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Summary 
Summary 
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is 
characterized by aggressive growth and poor prognosis. Despite progress in the medical 
management, treatment options are still limited and median survival for patients with 
advanced tumors is less than one year. New therapeutic interventions are therefore urgently 
needed. 
The cytosolic helicase retinoic acid-inducible gene I (RIG-I) is an immune receptor for viral 
5'-triphosphate-RNA (ppp-RNA) and its activation triggers innate and adaptive immunity via 
induction of type I interferon (IFN) and proinflammatory cytokines. In addition, it promotes an 
immunogenic form of cell death in tumor cells.  
This project focused on the development of a ppp-RNA targeting RIG-I for HCC therapy. The 
aims of the study were to evaluate RIG-I as a potential therapeutic target in murine and 
human HCC cell lines and to assess the efficacy and mode of action of a RIG-I-based 
immunotherapy in an orthotopic HCC mouse model. This work revealed that RIG-I is 
expressed in human HCC tissue as well as in murine (RIL-175, Hep-55.1C, Hepa1-6) and 
human HCC cell lines (Huh7, Hep3B). It could be demonstrated that ppp-RNA treatment 
leads to the induction of IFN-ȕ, MHC-I/HLA, IP-10 and cell death in all tested cell lines, 
indicating a functional RIG-I signaling pathway in HCC. After having established two 
orthotopic HCC mouse models (RIL-175- and Hep-55.1C-based), the efficacy and mode of 
action of ppp-RNA immunotherapy was investigated in vivo. It was demonstrated that mice 
bearing RIL-175 tumors strongly benefited from a systemic ppp-RNA therapy, whereas the 
immunotherapy did not show any effect in the Hep-55.1C model. The fundamental difference 
between the two models regarding the treatment efficacy could not be clarified in this work. 
Analysis of immune cell activation showed that splenic CD4+ and CD8+ T and NK cells, as 
well as NK cells at the tumor site were activated upon systemic ppp-RNA administration. 
However, depletion of NK cells did not alter the treatment effect. In contrast, the therapy was 
completely dependent on functional CD4+ and CD8+ T cells. This observation was 
corroborated by the fact that surviving mice surmounted a robust memory response upon 
rechallenge with the same tumor cells. Mice deficient for either MAVS or IFNAR1 still 
responded to therapy pointing towards an intra-tumoral rather than a host-specific RIG-I 
signaling response. The combination of RIG-I-based immunotherapy and PD-1 checkpoint 
inhibition resulted in a synergistic therapeutic effect in the RIL-175 mouse model, serving as 
a promising approach for a therapy in the clinical setting. In sum, this project provides 
evidence that ppp-RNA immunotherapy bears potential for the treatment of HCC deserving 
further evaluation. 
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1 Introduction 
1.1 Clinical occurrence of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is a primary and malignant tumor of the liver tissue and one 
of the most incident cancer types worldwide, with men being three times more affected than 
women. Causes for disease development are frequently based on chronic inflammatory 
reactions of the liver tissue. Liver cirrhosis, an irreversible scarring of the liver tissue, as 
consequence of chronic infections, is often the root cause for HCC development (Bertuccio 
et al., 2017; Sanyal et al., 2010; Venook et al., 2010). 
Patients suffering from chronic liver cirrhosis and/or hepatitis B infection are at high risk for 
hepatocellular carcinoma. The increase in incidence of HCC of recent years is also 
associated with non-alcoholic fatty liver disease (NAFLD) in the consequence of obesity. 
Non-alcoholic steatohepatitis (NASH) belongs to the group of NAFLD and is an inflammatory 
disease of the liver tissue potentially leading to the induction and progression of liver fibrosis 
and cirrhosis, respectively. Also hepatitis C-associated or alcohol consumption-induced liver 
cirrhosis poses an increased risk to consequently coming down with HCC (reviewed in 
Leitlinienprogramm Onkologie, 2013). 
1.2 Immune landscape of hepatocellular carcinoma  
The immune system plays a crucial role in the development of HCC. Some immunological 
aspects that positively favor tumor growth are summarized below.  
1.2.1 The immunosuppressive mircoenvironment of the liver 
The liver is the body's largest excretory organ. During its crucial role in the detoxification 
process of the body it is exposed to a massive number of antigens contained in the blood 
and toxins derived from metabolic processes and the intestine. The liver has therefore 
established an intrinsic tolerability in order to avoid damage from autoimmunity in the 
presence of harmless antigens. The tolerogeneity of naïve T cells is mediated by liver 
sinusoidal endothelial cells (LSEC), Kupffer cells and dendritic cells (DC) via antigen-
presentation. Further immunosuppressive mechanisms in order to inhibit T cell and NK cell 
activity include for example: the secretion of IL-10 by Kupffer cells and of TGF-ȕ by Kupffer 
cells and LSEC, the downregulation of the co-stimulatory molecule CD80 on the LSEC as 
well as the expression of the immune checkpoint inhibitor Programmed cell death 1 ligand 1 
(PD-L1) on hepatocytes, hepatic stellate cells and LSEC (Figure 1). All these factors 
mentioned, are supposed to also play an essential role in HCC development and for the 
tumor´s evasion from the host´s immune response (reviewed in Hato et al., 2014; Makarova-
Rusher et al., 2015).  
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Figure 1: Scheme of the immunosuppressive microenvironment of the liver. Depicted in simplified terms are 
the immunosuppressive mechanisms mediated by liver cells in order to inhibit T cell and NK cell activity which 
include the secretion of IL-10 by Kupffer cells and of TGF-ȕ by Kupffer cells and liver sinusoidal endothelial cells 
(LSEC), the downregulation of the co-stimulatory molecule CD80 on the LSEC as well as the expression of PD-L1 
on hepatocytes, hepatic stellate cells and LSEC (modified from Makarova-Rusher et al., 2015). 
 
1.2.2 Immune checkpoint surveillance in oncogenesis 
Chronic inflammation, such as HBV or HCV infection, is often the root cause for the 
development of primary liver cancer. Suppressive immune cells, for example regulatory 
T cells (Treg), attracted by the inflamed tissue, and the continuous expression of anti-
inflammatory cytokines, such as TGF-ȕ, positively impact tumor escape mechanisms and 
tumorigenesis. Recent findings suggest, that proteins involved in the immune checkpoint 
surveillance play a key role in mediating tumor evasion and progression. Focusing on the 
immune checkpoint receptor PD-1, it was shown that its expression on intrahepatic 
lymphocytes positively correlates with the degree of chronic viral infection and has also been 
linked to the reduced effector function of T cells. Building on recent findings, the expression 
of immune checkpoint inhibitors is thought to mediate immune tolerance to tumor antigens 
thereby promoting tumor growth. Several findings show that intra-tumoral myleoid derived 
suppressor cells (MDSC) and Treg inhibit the NK and T cell response via the PD-1/PD-L1 axis 
thereby helping tumor cells to evade the immune system. But also the immunosuppressive 
environment of the liver per se inhibits the lymphocyte-mediated tumor cell clearance through 
the expression of PD-L1 and the secretion of immunosuppressive cytokines by Kupffer cells, 
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hepatocytes, hepatic stellate cells and LSEC (reviewed in Hato et al., 2014; Makarova-
Rusher et al., 2015).  
1.3 Standard of care 
HCC is characterized by aggressive growth and poor prognosis. It is most of the time 
diagnosed at an advanced stage, which significantly limits treatment options. 
Treatment strategies are based on clinical stage of the tumor (Barcelona Clinic Liver Cancer 
Group classification) and performance status of the patient. Treatment is planned either in a 
curative intent or palliative if complete tumor control is unlikely to be achieved. Curative 
options include primary or secondary resection of tumor, liver transplantation or local ablation 
with either radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI), leading to 
a five-year survival of 50-70 %. Palliative treatment includes transarterial chemoembolisation 
(TACE), radioembolisation or systemic treatment with the tyrosine kinase inhibitor sorafenib. 
Systemic chemotherapy has proven little to no benefit. The median survival rate is around 16 
months. For patients with end stage liver disease the only option is best supportive care 
(BSC) with a survival rate less than three months (reviewed in Leitlinienprogramm Onkologie, 
2013).  
Several clinical trials have been conducted with the tyrosine kinase inhibitor sorafenib. 
Modest to effective and well tolerated results were observed depending on the severity of 
liver cirrhosis and metastatic spread (Abou-Alfa et al., 2006; Cheng et al., 2009; Llovet et al., 
2008; Pinter et al., 2009; Yau et al., 2009). As the first systemic therapy showing favor to the 
survival of patients suffering from advanced HCC, sorafenib was approved in 2005 by the 
Food and Drug Administration (FDA) and in 2007 by the European Medicines Agency (EMA) 
for the treatment of HCC (European Medicines Agency, 2011; Food and Drug Administration, 
2013; Kane et al., 2009), being now under suspicion to enhance metastasis formation 
(Zhang et al., 2012). In addition, since the last years, numerous cases have been reported in 
which HCC patients show resistance to sorafenib. The reason for this is still under 
investigation (reviewed in Chen et al., 2015). 
1.4 Immunotherapy of hepatocellular carcinoma 
Despite progress in the medical management, the incidence and the mortality rate of patients 
suffering from HCC are still increasing (Wong et al., 2017). New therapeutic approaches are 
therefore urgently needed. Novel concepts of the clinical development of HCC therapy 
strongly focus on immunotherapeutic strategies. The main approaches are summarized in 
the following. 
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1.4.1 Current concepts of clinical development 
1.4.1.1 Immunomodulators 
1.4.1.1.1 Interferons 
Interferons (IFN) are cytokines initially discovered by their anti-viral capacity. The anti-
tumoral potential of IFN-α, -ȕ and -Ȗ was investigated for HCC therapy and was reported to 
be sufficient by inducing tumor cell death. In this regard, the question which type of IFN is 
more efficient is still under debate. However, much more cases using IFN-α have been 
reported (reviewed in  Hong et al., 2015). IFN-α treatment alone was considered not to be 
sufficient for HCC therapy, but was reported beneficial in an adjuvant setting in combination 
with 5‐fluorouracil (Kasai et al., 2012; Obi et al., 2006; Sakon et al., 2002). Adjuvant IFN-α 
therapy was further described to be save and to prolong recurrence free period post-surgery 
and after TACE treatment for unresectable HCC (Lee et al., 2013; Li et al., 2009).  
1.4.1.1.2 Interleukins 
Interleukins are cytokines that are involved in the regulation of inflammation. These 
characteristics have been utilized for cancer therapy in order to boost the anti-tumoral 
immune response. However, only few clinical studies with low numbers of patients with HCC 
have been conducted so far (reviewed in Hong et al., 2015). Lygidakis et al. (1995) reported, 
that chemotherapy accompanied by high dose IFN-Ȗ and IL-2 induced tumor necrosis and 
led to the reduction of AFP serum levels in patients with advanced HCC. The same was seen 
in a study reported by Sangro et al. (2004), where nine patients with primary liver cancer 
were treated with an IL-12 producing adenovirus. In the context of an IL-based anti-tumor 
therapy further investigations and the conduct of clinical trials with sufficient patient numbers 
are needed to confirm existing data (reviewed in Hong et al., 2015). 
1.4.1.2 Cancer vaccines 
One further approach for the treatment of HCC is to take advantage of tumor-associated 
antigens (TAA) for the development of a cancer vaccine-based immunotherapy. Therefore, 
one challenge is the heterogeneity of HCC and thus pining down antigens which are 
characteristic and more or less specific for the tumor tissue. The most studied candidates 
reported for peptide-based vaccines are the TAA AFP, glypican 3 (GPC3) and telomerase 
reverse transcriptase (TERT), which are highly over-expressed in HCC (reviewed in Hong et 
al., 2015). The first pilot study with this in mind was reported by Butterfield et al. (2003) 
investigating the efficacy of T cells specific for a HLA-A-restricted AFP peptide in HCC 
patients. The study revealed a strong immune response mediated by AFP-specific T cells, in 
the sense that T cells specific for AFP and also their expansion could be demonstrated 
in vivo. Further studies in this context are ongoing. The major challenges will be to overcome 
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the immunosuppressive microenvironment of HCC and to identify more specific TAA for the 
induction of a strong CD8+ and also CD4+ T cell response. Also combinatorial strategies are 
currently under discussion (reviewed in Buonaguro et al., 2013). 
1.4.1.3 Checkpoint inhibition 
Huge progress has been made in melanoma immunotherapy during the last years, bringing 
also benefit for the treatment of several other solid tumor entities. Successful therapeutic 
approaches were made in regard to checkpoint inhibition with a special focus on the 
Programmed cell death protein 1 (PD-1)/Programmed cell death 1 ligand 1 (PD-L1) axis. 
Nivolumab and pembrolizumab are humanized monoclonal antibodies binding to the T cell 
receptor PD-1, which in turn interferes with the binding of PD-1 to its ligand PD-L1 in the 
tumor microenvironment, thereby blocking the tumor-mediated inhibition of T cell signaling. 
Binding of PD-1 to its ligand PD-L1, which is also expressed on antigen presenting cells, 
inhibits T cell receptor mediated IL-2 expression and T cell proliferation. This inhibition 
showed great success in prolonging survival and improving quality of life of patients with 
advanced melanoma. Both antibodies nivolumab and pembrolizumab have recently been 
approved by the EMA and the FDA for the treatment of melanoma (European Medicines 
Agency, 2017a, 2017b; Food and Drug Administration, 2017a, 2017b). Due to the great 
achievements made in melanoma research using checkpoint inhibitors, a logical 
consequence is trying to derive benefit for HCC treatment. Truong et al. (2016) reported first 
about a patient benefiting from pembrolizumab therapy after sorafenib treatment had failed. 
Several phase I/II and III studies are meanwhile ongoing using pembrolizumab and 
nivolumab, respectively, as single or concomitant therapy (ClinicalTrials.gov, 2018a, 2018b). 
El-Khoueiry et al. (2017) recently reported that the treatment with nivolumab led to a 
profound anti-tumor effect with an objective response rate of 15-20 % resulting in tumor 
reduction along with a positive impact on the overall survival of patients with advanced HCC. 
1.4.1.4 Chimeric antigen receptors 
One method used for immunotherapy of HCC is the adoptive transfer of immune cells. 
Cytokine-induced immune cells (CIK) produced and expanded from peripheral blood, tumor 
infiltrating lymphocytes (TIL) isolated from tumor tissue and engineered T cells genetically 
modified to express a tumor-specific chimeric antigen receptor (CAR) are examined 
(reviewed in Prieto et al., 2015). The latter, also known as CAR T cells, have already been 
successfully used in hemato-oncological malignant diseases (Maus et al., 2014). CAR T cells 
directed against the tumor-associated antigen (TAA) glypican 3 (GPC3) were already tested 
in mouse models of HCC opening up a promising therapeutic option (Li et al., 2018). First 
results from clinical studies in the context of HCC therapy are yet to come. 
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1.4.1.5 Oncolytic viruses 
A new approach in the field of immunotherapy is the use of oncolytic viruses (OV). These are 
viruses bearing a natural tropism for cancer cells and viruses whose capsid has been 
engineered carrying proteins that bind to tumor specific receptors, respectively. The infection 
of tumor cells with OV induces an immunogenic form of cell death: upon infection of tumor 
cells and subsequent cell lysis, antigen presenting cells (APC) recognize damage-associated 
molecular patterns (DAMP) derived from lysed tumor cells and pathogen-associated 
molecular patterns (PAMP) derived from the oncolytic viruses. As a consequence, 
CD8+ T cell priming takes place in secondary lymphoid organs by the activated APC resulting 
in a tumor antigen-specific T cell response. In addition, CD8+ T cells are recruited by the 
upregulation of MHC class I on the tumor cell surface due to the viral infection, which leads 
to a T cell receptor (TCR)-mediated killing of tumor cells (reviewed in Bommareddy et al., 
2018). In 2015 the first OV-based immunotherapy for the treatment of melanoma was 
approved by the FDA (Pol et al., 2016). In the context of HCC therapy, Zhang et al. (2017) 
showed that the treatment with an OV sensitized towards HCC at low MOI results in an 
enhanced oncolytic capacity and effectively kills HCC cells in vitro and in vivo. In addition, 
the OV-based therapy revealed a tolerable safety profile in non-human primates. Abdullahi et 
al. (2018) recently reported on a novel chimeric OV for HCC therapy with an enhanced safety 
profile regarding off-target effects in liver and brain. Another approach was taken by Chen et 
al. (2017) who successfully combined OV therapy with adoptive T cell transfer to enhance 
the anti-tumoral capacity of the adopted T cells in an HCC mouse model. 
1.4.2 RIG-I-like helicases for the therapy of hepatocellular carcinoma 
One possible way to direct the immune system against the tumor is to mimic a viral infection 
of the tumor tissue itself. The immune system offers a plethora of germline-encoded 
receptors for the detection and elimination of invading pathogens such as bacteria and 
viruses called pathogen recognition receptors (PRR). The detection of certain viruses is 
carried out, amongst others, via so called retinoic acid-inducible gene I (RIG-I)-like helicases 
(RLH) with its well-described members RIG-I and melanoma differentiation-associated 
antigen 5 (MDA5) (reviewed in Takeuchi and Akira, 2008). The activation of RLH in tumor 
cells bears potential for anti-tumor immunotherapy. The actual concept is described below. 
1.4.2.1 Biology and function of RIG-I-like helicases 
RIG-I and MDA5 are ubiquitously expressed cytoplasmic receptors which induce antiviral 
immune responses by sensing viral nucleic acids. This results in an adaptive immune 
response and induces apoptosis of infected cells. The helicases are composed of: a 
N-terminal caspase-recruitment domain (CARD) responsible for signaling transduction, a 
conserved helicase domain and a C-terminal regulatory domain (CTD), which unfolds and 
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senses bound viral nucleic acid (Luo et al., 2011). A special focus in this work is on the 
cytosolic helicase RIG-I, which is the ligand of double-stranded 5'-triphosphate- and double-
stranded 5'-diphosphate-RNA (Goubau et al., 2014; Hornung et al., 2006). Activation of RIG-I 
leads to downstream signaling via the mitochondrial antiviral-signaling protein (MAVS) and 
activates the transcription factors IFN regulatory factor 3 and 7 (IRF3/7), Nuclear factor 
kappa-light-chain-enhancer of activated B-cells (NF-țB), and Mitogen-activated protein 
(MAP) kinase signaling (Schmidt et al., 2009). This leads to the secretion of type I IFN and 
inflammatory cytokines, such as IP-10, triggering an adaptive immune cell response by the 
attraction and activation of dendritic cells (DC) and natural killer cells (NK cells). This again 
leads to the recruitment of cytotoxic T lymphocytes (CTL) via IFN-Ȗ secretion (reviewed in 
Iwasaki and Medzhitov, 2010; Kaneda, 2013). For the sake of completeness, I want to also 
mention the third member of the RLH-family: laboratory of genetics and physiology 2 (LGP2). 
This protein differs in structure from the other two RLH, as it lacks a CARD domain. LGP2 is 
thought to act as a regulator of RIG-I and MDA5 during RLH signaling, but its exact function 
is not yet fully elucidated (reviewed in Ahmad and Hur, 2015). 
1.4.2.2 RIG-I as target structure for therapy of hepatocellular carcinoma 
The activation of RIG-I bears therapeutic potential, since its signaling pathway triggers an 
adaptive immune response and leads to the induction of apoptosis of infected cells, as 
already described in section 1.4.2.1. Mimicking a viral infection by synthetic or 
in vitro-transcribed RNA sensed by RLH, has been shown to induce the intrinsic 
mitochondrial apoptosis pathway leading to tumor cell death (Besch et al., 2009). In addition, 
our research group could recently demonstrate that therapy of pancreatic tumors with RLH 
ligands induced a form of immunogenic tumor cell death with enhanced antigen presentation 
by DC and activation of tumor-directed T cells. Furthermore, it sensitized tumor cells towards 
CD95-mediated killing by immune cells in vitro (Duewell et al., 2014). In addition the 
modification of siRNA as 5'-triphosphate-siRNA (5’-ppp-siRNA) allows combining gene 
silencing of oncogenic target genes with RIG-I activation via the 5’-ppp moiety (Duewell et 
al., 2014; Ellermeier et al., 2013; Petrocca and Lieberman, 2008; Poeck et al., 2008) 
(Figure 2). 
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Figure 2: Dual activities of bifunctional 5’-ppp-siRNAs. Upon transfection into the cytosol, the 5’-ppp-siRNA 
can activate RIG-I, leading to NF-țB, IRF3/7 and MAPK signaling and the induction of intrinsic apoptosis. In 
addition, via incorporation into the RISC complex the 5’-ppp-siRNA leads to degradation of targeted mRNA with 
subsequent gene silencing (modified from Petrocca and Lieberman, 2008). 
 
To what extent HCC is susceptible to such an immunotherapeutic approach is the subject of 
current research. Hou et al. (2014) revealed that RIG-I expression is positively correlated 
with the overall survival of HCC patients and serves as prognostic marker in regard to the 
effectiveness of an IFN-α-based therapy. Similar findings concerning the prognosis and the 
overall survival of patients suffering from HCC were made by Liu et al. (2015). In addition the 
same group demonstrated that increased levels of RIG-I minimized the proliferative and 
metastatic potential of the tumor by down-regulating the Matrix metalloproteinase-9 (MMP-9), 
a protein which is critically involved in the process of tumor migration and invasion (reviewed 
in Deryugina and Quigley, 2006). RIG-I is therefore not only suggested as prognostic marker, 
but also as therapeutic target (Hou et al., 2014; Liu et al., 2015). In this context, the intra-
lesional administration of a synthetic RNA oligonucleotide-based RIG-I agonist is currently 
tested for its tolerability and safety in patients with injectable liver tumors or liver 
metastases in a phase I/II study (ClinicalTrials.gov, 2018c). In this regard the therapy´s 
efficacy and its immune mediated effector mechanisms in the liver related to its immune-
privileged characteristics are still to be examined. Initial efforts have already been made by 
our group to show that a RIG-I-based immunotherapy is a promising therapeutic option for 
hepatocellular carcinoma (Funk, β01κ; Lazić, β017). 
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1.4.2.3 RIG-I agonists in comparison to TLR and STING agonists 
Next to RIG-I other PRR were explored for the utility in the context of immunotherapy for 
cancer. In particular, Toll-like receptors (TLR) and cGas are also worth to be mentioned.  
TLR sense pathogen-derived DNA, lipopolysaccharide and other pathogen-associated 
molecular patterns (reviewed in Takeda and Akira, 2004). TLR agonists are reported to have 
highly anti-tumoral potential (reviewed in Krieg, 2008) and some have already made it into 
clinical trials. In the context of HCC, TLR3 and TLR4 have been reported as valuable 
potential targets for anti-tumor therapy in preclinical studies (reviewed in Zou et al., 2016). 
One critical point to consider is that some TLR are highly expressed on tissue of some tumor 
types and are under suspicion to promote tumor growth and migration (Kaczanowska et al., 
2013). TLR as therapeutic target in HCC remains controversial, as for example several 
studies demonstrated the anti-tumoral potential of TLR2 signaling in HCC (reviewed in Zou et 
al., 2016). In contrast, Huang et al. (2012) demonstrated that knocking down TLR2 reduces 
metastasis formation in vivo. The same applies to TLR9 and TLR7: both proteins have been 
reported as being critically involved in tumor promotion as well as tumor inhibition (reviewed 
in Zou et al., 2016). However, Tada et al. (2012) reported on a phase I/II clinical trial 
combining antigen pulsed DC with a TLR7 agonist for the treatment of patients suffering from 
HCC. The study revealed a tolerable safety profile, a TAA-specific T cell response but only a 
clinical response in one of five patients. The latter is maybe due to the advanced stage of 
HCC. To our knowledge, no further clinical trials in context of HCC therapy with TLR agonists 
have been reported so far.  
The PRR cGas activates STING upon recognition of cytosolic DNA resulting in the induction 
of type I IFN. Regarding cancer therapy, STING agonists are controversial for anti-tumor 
therapy, but are shown to be effective in combination with checkpoint inhibitors for tumors 
unsusceptible to PD-1 blockade (Fu et al., 2015). One major drawback in comparison to RLH 
is that some cancer types are impaired or even defective of STING signaling (reviewed in 
Baird et al., 2017). Especially HCC tissue is reported to have decreased STING expression 
(reviewed in He et al., 2017). 
A major advantage of ppp-RNA-based RIG-I agonists in comparison to TLR and cGas 
agonists is the technical possibility to modify ppp-RNA as 5'-triphosphate-siRNA 
(5’-ppp-siRNA) thereby combining RIG-I activation and RNAi-mediated gene silencing in one 
molecule as already described in section 1.4.2.2. The therapeutic efficacy of bifunctional 
5´-ppp-siRNAs has been successfully demonstrated for various tumor models. Studies 
revealed a more potent anti-tumoral effect mediated by bifunctional 5´-ppp-siRNA treatment 
as compared to solely inhibiting gene expression or activating RIG-I, respectively (Ellermeier 
et al., 2013; Meng et al., 2014; Petrocca and Lieberman, 2008; Poeck et al., 2008). Lazić 
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(2017) recently demonstrated that silencing c-Met, a well-known proto-oncogene in HCC, 
favors survival of liver tumor-bearing mice. The systemic treatment with bifunctional 
5´-ppp-c-Met-siRNA even showed a stronger effect in the induction of tumor cell death than 
treatment with ppp-RNA alone. 
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2 Objectives 
The long term goal of this project is to establish novel bifunctional 5´-ppp-siRNA-based 
therapeutics for the treatment of HCC that combine two  modes  of  action:  activation  of  the  
innate  immune  response via RIG-I signaling and interfering with pro-tumorigenic 
mechanisms by gene silencing via RNA interference.   
During my Ph.D. studies I focused on the efficacy and mechanisms of action of RIG-I-based 
immunotherapy in murine HCC models. Following aims and questions were addressed:  
1. Evaluation of RIG-I as target in HCC:  
 Is RIG-I expressed in human HCC tissue? 
 Is RIG-I signaling functional in human and murine HCC cell lines?  
 What is the functional outcome of RIG-I activation concerning viability and 
proliferation of tumor cells?  
2. Establishment of orthotopic HCC mouse models   
3. Assessment of the efficacy of RIG-I-based immunotherapy in vivo:  
 How do RIG-I ligands affect tumor growth and survival of tumor-bearing mice?  
 What are the immunological effects induced by this therapy?  
 Which types of immune cells are activated upon ppp-RNA therapy? 
 Which immune cells play a key role in the therapeutic setting? 
 Does the therapy induce an immunological memory? 
 What is the therapy´s toxicity profile? 
 Can therapeutic effects be improved in combination with checkpoint 
inhibitors?
19 
Material 
3 Material 
3.1 Instruments 
Device name Manufacturer 
Blotting system Bio-Rad, Germany 
Cell culture CO2 incubator (BD 6220) Heraeus, Germany 
Cell culture Laminar Flow Thermo Scientific, Germany 
Centrifuge (Multifuge 3L-R) Thermo Scientific, Germany 
Centrifuge (5424 and 5415R) Eppendorf, Germany 
ELISA reader (Mithras LB940) Berthold Technologies, Germany 
FACSCanto II BD Bioscience, Germany 
Gel electrophoresis system peqlab, Germany 
Lightcycler® 480 II Roche, Germany 
Microscope Axiovert25 and Axiovert200M Zeiss, Germany 
Microscope TCS SP5 II Leica, Germany 
NanoDrop® 2000c Thermo Scientific, USA 
pH meter WTW, Germany 
Power Pac Basic Bio-Rad, Germany 
Thermocycler T3 Biometra, Germany 
Thermomixer Eppendorf, Germany 
Vortex Genie 2 Scientific Industries, Germany 
Western blot analyzer (LAS4000 mini) FujiFilm, Germany 
ChemiDoc™Touch Imaging system BioRad, Germany 
Isofluran evaporator, VP series Bioseb, USA/Canada 
gentleMACS Dissociator Miltenyi Biotec, Germany 
3.2 Technical equipment 
Name Manufacturer 
C Tubes (gentleMACS) Miltenyi Biotec, Germany 
Cannula Sterican, single-use, 0,40 x 20 mm B. Braun, Germany 
Cover glass VWR, Germany 
Gel blotting paper Whatman Paper GmbH, UK 
Immobilon®-PSQ Transfer Membrane, PVDF, 
pore size 0.2 µm 
Merck, Germany 
Insulin syringe 0.3 ml (U-100), 29 G Terumo, Germany 
Insulin syringe 1 ml (U-40), 29 G Terumo, Germany 
Microscope slides Superfrost® Plus Menzel- Thermo Fisher Scientific, USA 
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Gläser 
Nitrocellulose membrane AmershamTM-
Hybond®-ECL™, pore size 0.45 ȝm GE Healthcare, Germany 
Rot®-PVDF, pore size 0.45 ȝm Carl Roth, Germany 
Scalpel (No. 22) Feather, Japan 
Suture material (Prolene 5-0) Ethicon, USA 
Syringes Omnifix, 1 ml B. Braun, Germany 
 
3.3 Chemicals and reagents 
Chemical product Manufacturer 
Accutase eBioscience, USA 
Annexin Binding Buffer 10 x eBioscience, USA 
BD PharmLyse Lysis Buffer (10x 
concentrate) BD Biosciences, Germany 
Bromophenol blue Sigma-Aldrich, Germany 
Collagenase type I Sigma-Aldrich, Germany 
cOmplete™, Mini Protease Inhibitor Cocktail Roche, Germany 
DNase I recombinant Roche, Germany 
EDTA Sigma-Aldrich, Germany 
Ethanol p.a. Sigma-Aldrich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, Germany 
FACSClean BD Biosciences, Germany 
FACSFlow BD Biosciences, Germany 
Glycerol Carl Roth, Germany 
In vivo-JetPEITM Polyplus transfection, USA 
Isoflurane-CP® CP-Pharma, Germany 
Isopropanol p.a. Applichem, Germany 
KAPA PROBE FAST Universal qPCR 
Master Mix 
Peqlab Biotechnologie, Germany 
Lipofectamine® RNAiMax Transfection 
Reagent 
Thermo Fisher Scientific, USA 
Methanol Sigma-Aldrich, Germany 
NP-40 Abcam, UK 
PageRuler™ Plus Prestained Protein Ladder Thermo Scientific, USA 
Paraformaldehyde (PFA) Merck, Germany 
Phosphate Buffered Saline (PBS), (1x) Lonza, Switzerland 
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Powdered milk, blotting grade, low fat Carl Roth, Germany 
Propidium iodide Immuno Tools, Germany 
Sodium chloride Merck, Germany 
Sodium deoxycholate Sigma-Aldrich, Germany 
Sodium dodecyl sulfate (SDS) Merck, Germany 
Sodium orthovanadate Sigma-Aldrich, Germany 
Temgesic (Buprenorphin) RB Pharmaceuticals, UK 
Tris base Carl Roth, Germany 
Triton®-X 100 BioRad, Germany 
Trypan blue Sigma-Aldrich, Germany 
Trypsin-EDTA(10x) PAA, Austria 
Tween® 20 Roth, Germany 
ȕ-Mercatptoethanol Carl Roth, Germany 
 
3.4 Cell culture 
3.4.1 Cell lines 
Name Origin Distributor 
Hepa1-6 mouse Kindly provided by Dr. Mike Helms, Sanofi, Germany 
Hep-55.1C mouse CLS Cell Lines Service, Germany 
RIL-175 mouse 
Kindly provided by Prof. Tim Greten, Center for Cancer 
Research at the National Cancer Institute, USA and Nicolas 
Melin, Visceral and Transplantation Surgery, University of Bern, 
Switzerland 
Hep3B human Kindly provided by Dr. Mike Helms, Sanofi, Germany 
HepG2 human Kindly provided by Dr. Mike Helms, Sanofi, Germany 
HuH7 human Kindly provided by Dr. Mike Helms, Sanofi, Germany 
3.4.2 Media and supplements 
Name Manufacturer 
Ciprofloxacin Kabi (200 mg/ml) Fresenius Kabi, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM), high glucose Roth, Germany 
Gibco™ Fetal bovine serum Thermo Fisher Scientific, USA 
Gibco™ Opti-MEM™ I Reduced Serum 
Media 
Thermo Fisher Scientific, USA 
L-glutamine (200 mM) PAA, Austria 
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Lonza BioWhittaker™ Dulbecco's Modified 
Eagle's Medium with 4.5g L-Glucose per 
Liter, without L-Glutamine 
Lonza, Switzerland 
Lonza BioWhittaker™ RPMI 1640 without L-
Glutamine 
Lonza, Switzerland 
Phosphate Buffered Saline (PBS), (1x) Lonza, Switzerland 
 
Plastic material for cell culture was purchased from BD Bioscience (Germany), Corning 
(USA), Eppendorf (Germany), Greiner Bio-One (Germany) or Sarstedt (Germany). 
3.5 Kits 
Name Manufacturer 
DC Protein Assay BioRad, Germany 
HiScribe™ T7 Quick High Yield RNA 
Synthesis Kit 
New England Biolabs, Germany 
Klenow Fragment, exo– (5 U/µL) Thermo Fisher Scientific, USA 
Oligo Clean-Up and Concentration Kit (Cat. 
34100-NB) Norgen Biotek Corp., Canada 
RevertAid H Minus First Strand cDNA 
Synthesis Kit 
Thermo Fisher Scientific, USA 
RNA Clean-Up and Concentration Kit (Cat. 
43200-NB) Norgen Biotek, Canada 
SuperSignal™ West Femto Maximum 
Sensitivity Substrate 
Thermo Fisher Scientific, USA 
Total RNA Kit, peqGOLD Peqlab Biotechnologie, Germany 
3.6 Antibodies 
3.6.1 FACS analysis 
Specificity Fluorochrome Clone Isotype c [mg/ml] 
Mouse CD103 APC 2E 7 Hamster IgG 0.2 
Mouse CD11c PerCP N418 Hamster, IgG 0.2 
Mouse CD178 PE MFL3 Hamster, IgG 0.2 
Mouse CD19 PE/Cy7 6D5 Rat IgGβa, ț 0.2 
Mouse CD19 FITC 1D3 Rat IgGβa, ț 0.5 
Mouse CD25 FITC PC61 Rat IgG1, Ȝ 0.5 
Mouse CD279 APC 10F.9G2 Rat IgGβb, ț 0.2 
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Mouse CD3 APC 17A2 Rat IgGβb, ț 0.2 
Mouse CD3 PB 17A2 Rat IgGβb, ț 0.5 
Mouse CD4 PE/Cy7 RM4-5 Rat IgGβa, ț 0.2 
Mouse CD4 FITC RM4-5 Rat IgGβa, ț 0.5 
Mouse CD45 PB 30-F11 Rat IgGβb, ț 0.5 
Mouse CD45 PE 30-F11 Rat IgGβb, ț 0.2 
Mouse CD69 FITC H1.2F3 Hamster IgG1, Ȝ 0.5 
Mouse CD8 PerCP 53-6.7 Rat IgGβa,ț 0.2 
Mouse CD8 APC 53-6.7 Rat IgGβa, ț 0.2 
Mouse CD86 FITC GL1 Rat IgGβa, ț 0.5 
Mouse CD95 PE/Cy7 Jo2 Hamster IgGβ, Ȝ 0.2 
Mouse F4/80 APC BM8 Rat IgGβa, ț 0.2 
Mouse Gr-1 PE RB6-8C5 Rat IgGβb, ț 0.2 
Mouse H-2Kb FITC AF6-88.5 Mouse IgGβa, ț 0.5 
Mouse I-A/I-E PE M5/11.15.2 Rat IgGβb, ț 0.2 
Mouse NK-1.1 PerCP PK136 Mouse IgGβa, ț 0.2 
Mouse/human CD11b PE/Cy7 M1/70 Rat IgGβb, ț 0.2 
Mouse/rat Foxp3 PE FJK-16s Rat IgGβa, ț 0.5 
 
Annexin V, APC conjugate was purchased from Immuno Tools (Germany).  
All antibodies and their respective IgG isotype controls were purchased from BioLegend 
(USA), BD Pharmingen (USA), BD Biosciences (USA) or eBioscience (USA).  The viability 
dye Fixable Viability Dye eFluor® 780 was purchased from eBioscience (USA). TruStain 
FcX™ (anti-mouse CD16/32) antibody was purchased from BioLegend (USA) and used in 
accordance with the manufacturer´s instructions. 
3.6.2 Functional assays 
Specifity Clone Isotype Function 
Mouse CDκα YTS 169.4 Rat IgG2b Depletion 
Mouse CD4 GK1.5 Rat IgG2b Depletion 
Mouse NK-1.1 PK136 Mouse IgG2a Depletion 
Mouse CD279  RMP1-14 Rat IgG2a Blocking 
Mouse CD95 Jo2 Hamster IgG2, Ȝ Activation 
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In vivo antibodies and IgG isotype controls were purchased from BioXcell (USA). Anti-mouse 
CD95 antibody and respective IgG isotype control were purchased from BD Pharmingen 
(USA). 
3.6.3 Western blot analysis 
Specificity Clone Isotype Modification c [µg/ml] 
Human, mouse, rat RIG-I D-12 mAb IgG1 None 200 
Human, mouse RIG-I Alme-1 mAb IgG1 None 1000 
Human, mouse, ȕ-Actin C4 mAb  HRP 200  
 
All primary antibodies were purchased from Santa Cruz Bioctechnology (USA) and Adipogen 
Life Sciences (Switzerland), respectively. As secondary antibody goat anti-mouse IgG-HRP 
from Santa Cruz Bioctechnology (USA) was used. 
3.7 Software 
Software name Provider 
FlowJo 10.0 FloJo LLC, USA 
GraphPad Prism 5.0 GraphPad Software, USA 
Image Lab™ BioRad, Germany 
ImageJ Wayne Rasband and Cuertis Rueden 
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4 Methodology 
4.1 Animal experiments 
4.1.1 Animals 
C57BL/6JRi mice were purchased from Janvier Labs, France. Ifnar1r-/- and Mavs-/- mice were 
kindly provided by Ulrich Kalinke (Institute for Experimental Infection Research, TWINCORE, 
Centre for Experimental and Clinical Infection Research, Hannover Medical School). 
NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ (NOD-scid IL2Rγnull, NSG) mice were provided by the animal 
facility´s own breeding. 
All animal studies were approved by the local regulatory agency (Regierung von Oberbayern, 
Munich, Germany; experimentation application number 55.2-1-54-2532-52-2013). 
4.1.2 In vivo experiments 
4.1.2.1 Orthotopic tumor implantation 
For orthotopic tumor implantation, cells were harvested with accutase and washed twice with 
PBS. Cell number was adjusted as follows: 
- RIL-175:  5 x 105 cells/20 µl PBS 
- Hep-55.1C:  2 x 106 cells/20 µl PBS 
- Hepa1-6:  1 x 106 cells/20 µl PBS. 
20 µl cell suspension were injected into the left liver lobe using a Hamilton syringe. Mice 
were sutured with Prolene 5 - 0 from Ethicon. 
Surgical procedure was performed under Isoflurane anaesthesia. For peri-operative pain 
management 0.125 mg/kg Buprenorphin in NaCl 0.9 % were injected before and 24 h and 48 
h after surgery. 
4.1.2.2 Subcutaneous tumor induction 
For subcutaneous tumor induction cells were prepared as for orthotopic tumor implantation 
(see section 4.1.2.1). 5 x 105 RIL-175 cells were injected subcutaneously with a 29 Insulin 
syringe into the flank of mice. 
4.1.2.3 CT imaging 
CT imaging of orthotopic liver tumors was performed in collaboration with Prof. Kirsten 
Lauber and Dr. Benjamin Stegen, Department of Radiation Oncology, LMU Munich. For this 
purpose, mice were anesthetized with isoflurane. Iodine was used as contrast agent and was 
injected i.v. prior to imaging. 
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4.1.3 Ex vivo analysis 
4.1.3.1 Single cell preparation from tumor and spleen 
For single cell preparation from tumors, tissue was minced and transferred to a 
gentleMACS™ C Tube containing a DNase-Collagenase-mix. Tissue preparation was 
performed according to the protocol of the Tumor dissociation Kit, mouse from Miltenyi 
Biotec using a DNAse-Collagenase-mix instead of the enzyme mixes provided by the kit. 
DNase-Collagenase-mix: 
1 mg/ml Collagenase Type I 
100 U/ml DNase I 
in RPMI 1640 
 
For single cell preparation from spleen, tissue was mashed through a 40 µm cell strainer and 
flushed with 10 ml 10 % FBS in PBS. The cell suspension was centrifuged at 400 g for 5 min 
at RT. Cells were directly used for lysis of erythrocytes using the BD Pharm Lyse™ Buffer 
according to the manufacturer´s instructions. 
4.2 Cell culture 
Tumor cells were cultured in DMEM medium supplemented with 10 % FBS and 10 µg/ml 
ciprofloxacin under the following conditions: 
- 37°C 
- 10 % CO2 
- 95 % humidity. 
4.3 Immunological methods 
4.3.1 Enzyme-linked immunosorbent assay 
For the detection of IP-10 (CXCL10) in the supernatant or plasma an enzyme-linked 
immunosorbent assay (ELISA) was performed. For murine samples the CXCL10 ELISA Kit 
from R&D Systems, for human samples the OptEIA™ Human IP-10 ELISA from BD 
Biosciences was used. The assay was performed according to the manufacturer´s 
instructions except that only half of the volume of the reagents specified by the manufacturer 
was used. Samples were diluted. 
4.3.2 Flow cytometry 
4.3.2.1 Staining of extra- and intracellular proteins 
Cells were washed with 1 ml FACS buffer and centrifuged (5 min, 400 g, RT). Cells were 
incubated with FACS buffer containing a live-dead-stain and diluted antibodies for 20 min at 
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RT. Subsequently cells were washed with 1 ml FACS buffer and centrifuged (5 min, 400 g, 
RT). Samples were directly used for flow cytometric analysis or prepared for intracellular 
staining using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to 
the manufacturer´s instructions. 
All antibodies were diluted 1:200 for flow cytometry. Except anti-FoxP3 antibody was diluted 
1:40. Respective IgG isotypes served as control. For discrimination of living and dead cells 
the Fixable Viability Dye eFluor® 780 (eBioscience) was used 1:1000. For ex vivo analysis, 
cells were incubated with TruStain FcX™ antibody (BioLegend) prior to staining according to 
the manufacturer´s instructions. For the analysis of FasL, FACS buffer was supplemented 
with 1 x cOmplete™, Mini Protease Inhibitor (Roche). 
FACS buffer: 
0.5 g sodium azide 
2 ml EDTA (0.5 M) 
5 ml FBS 
ad 500 ml PBS 
 
4.3.2.2 Annexin V/PI staining 
For Annexin V staining cells were prepared as recommended by the manufacturer. 1 µl PI 
(250 ng/ml) was added directly before analysis.  
4.3.3 Immunhistochemistry 
For immunohistochemical analysis of human HCC tissue 239 human tissue microarrays 
(TMA) were investigated: 179 samples were provided by PD Dr. Enrico de Toni, Liver 
Center, LMU Munich and 60 by the Department of Pathology, LMU Munich. 
Immunohistochemical preparation of human TMA was performed by Prof. Doris Mayr, 
Department of Pathology, LMU Munich. Analysis was performed by Dr. Lars König, Division 
of Clinical Pharmacology, LMU Munich. For the detection of RIG-I mAb IgG1, clone Alme-1 
was used. Analyzed were two biopsy punches per patient from different tumor regions.  
4.3.4 Western blot analysis 
4.3.4.1  Preparation of protein lysates 
To extract proteins, cells were lysed with supplemented RIPA or NP-40 buffer. Whole cell 
lysates were centrifuged (20 min, 16,000 rpm, 4°C) in a benchtop centrifuge and 
supernatants were collected. The concentration of proteins was determined using the DC 
Protein Assay from BioRad. Protein lysates were either stored at -20°C or directly used for 
western blot analysis. 
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RIPA buffer: 
150 mM sodium chloride 
1.0 % (v/v) Triton X-100  
0.5 % (w/v) sodium deoxycholate 
0.1 % (w/v) SDS  
50 mM Tris, pH 8.0 
 
NP-40 buffer: 
150 mM sodium chloride 
1.0 % (v/v) NP-40  
50 mM Tris pH 8.0 
 
Supplements: 
1 x proteinase inhibitors (cOmplete™, Mini Protease Inhibitor Cocktail, Roche) 
4.3.4.2 SDS-PAGE 
30 µg of whole proteins were mixed with appropriate amount of 6 x Laemmli loading buffer 
and denaturated at 95°C for 5 min. Samples were loaded on a SDS gel (10-12 %) and 
separated by an applied voltage of 100 V for 1.5 h. The PageRuler™ Plus Prestained Protein 
Ladder (Thermo Fisher Scientific) was used as reference.  
Laemmli buffer (6 x): 
7 ml Tris (0.5 M) 
1 g SDS 
3 ml glycerol 
1.2 mg bromophenol blue 
680 µl β-mercatptoethanol 
 
Running buffer: 
248 mM Tris 
14 mM SDS  
1.92 M glycine 
 
4.3.4.3 Protein transfer 
Proteins were transferred from the SDS gel to a nitrocellulose membrane or a PVDF 
membrane, which was previously activated in methanol, applying 250 mA for 1.5 h. 
Subsequently, the membrane was rinsed with distilled water. It was then washed three times 
for 10 min each in TBS-T. The membrane was incubated rotating in blocking buffer for 1 h at 
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RT or at 4°C over night. The primary antibody (diluted in blocking buffer) was incubated over 
night at 4°C rotating. Afterwards, the membrane was incubated in TBS-T for 10 min at RT. 
This step was repeated two times. The secondary antibody (diluted in blocking buffer) was 
incubated for 60 min at RT rotating. The membrane was incubated in TBS-T for 10 min at RT 
three times each. Afterwards it was incubated in TBS for another 10 min. The antibody signal 
was developed using the SuperSignal™ West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific) according to the manufacturer´s instructions. The analysis of 
protein bands was performed using the western blot analyzer LAS4000 mini (FujiFilm) and 
the ChemiDoc™Touch Imaging system (BioRad), respectively. 
Transfer buffer (20 x): 
198 mM Tris 
2 M glycine 
 
TBS: 
50 mM Tris  
150 mM NaCl  
HCL (ad pH 7.6) 
 
Washing buffer (TBS-T): 
TBS 1 x 
0.5 % (v/v) Tween 20  
 
Blocking buffer: 
5 % (w/v) powdered milk in TBS-T  
4.4 Molecular biological methods 
4.4.1 RNA isolation 
RNA from cultivated cells and tissue was isolated using the Total RNA Kit from Peqlab 
according to the manufacturer´s instructions.  
4.4.2 cDNA synthesis 
cDNA was synthesized using the RevertAID™ First strand cDNA Synthesis kit (Thermo 
Fisher Scientific) according to the manufacturer´s instructions. 
4.4.3 Relative quantification of mRNA levels 
Relative mRNA expression levels were analyzed via quantitative real time-PCR (qRT-PCR) 
using the KAPA PROBE FAST qPCR Kit (Peqlab). Probes required for qRT-PCR were 
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purchased from Roche and oligonucleotides were therefore designed with respect to the 
Roche Library.  
Probes and sequences of the oligonucelotides used are listed below: 
Gene Species Forward (5´ -> 3´) Reverse (5´ -> 3´) 
ifnb1 
human CTT TGC TAT TTT CAG ACA AGA TTC A GCC AGG AGG TTC TCA ACA AT 
mouse GCA GAA CTG GAA CAG GTC GT TGT TCG AAG TCC GGG ATG 
ddx58 mouse CAC AGT GTC AAT GCC TCC AA TTG CTG ACC CAG AAG ATG G 
actb 
human CCA ACC GCG AGA AGA TGA CCA GAG GCG TAC AGG GAT AG 
mouse CTA AGG CCA ACC GTG AAA AG ACC AGA GGC ATA CAG GGA CA 
All oligonucleotides were purchased from Eurofins Genomics. 
For each sample a reaction mixture was prepared as follows: 
Reagent Volume [µl] 
KAPA PROBE FAST Universal qPCR 
Master Mix (2 x) 5.0 
Primer forward (100 ȖM) 0.2 
Primer reverse (100 ȖM) 0.2 
Probe 10 x 0.1 
H2Oddest ad 10 
2 µl cDNA diluted 1:2 in H2Oddest were added. Expression of mRNA was assessed using the 
LightCycler® 480 (software Version 1.5) from Roche and the detection format ‘monocolor 
hydrolysis probes’.  
Program settings are described in the table below:   
Number of cycles Temperature [°C] 
1 95 
45 60 
1 40 
Relative mRNA expression levels were calculated taking the primer efficiency, prior 
calculated via a relative standard curve, into account. 
4.4.4 In vitro transcription  
The respective DNA template for generating the 5´-triphosphate-RNA (ppp-RNA) was 
purchased from Eurofins Genomics with the following sequence (CO4hp): 
5´-GCG CTA TCC AGC TTA CGT A GAGCTC T ACG TAA GCT GGA TAG CGC TAT AGT 
GAG TCG TAT TA-3´. It was annealed to a T7 promoter primer with the following sequence: 
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5´-TAA TAC GAC TCA CTA TA-3´. A double-stranded DNA-template was generated using 
the Klenow Polymerase from Thermo Fisher Scientific according to the manufacturer´s 
instructions. 
Alternatively, the sense and antisense CO4hp-template strands were annealed to form the 
double-stranded DNA-template. 
The ppp-RNA was generated via in vitro-transcription (IVT) using the HiScribe™ T7 Quick 
High Yield RNA Synthesis Kit from New England Biolabs GmbH according to the 
manufacturer´s instructions with a template concentration of 1 µM.  
The RNA was purified using the RNA Clean-Up and Concentration Kit from Norgen Biotek 
according to the manufacturer´s instructions. 
4.4.5 Transfection of RNA 
One day prior to transfection cells were seeded in appropriate culture dishes in cell culture 
medium. On day of transfection medium was changed to transfection medium. Cells were 
transfected with RNA using Lipofectamin® RNAiMax (Thermo Fisher Scientific) according to 
the manufacturer´s instructions. For transfection of 40 nM RNA 3 µl transfection reagent 
were used. The same N/P-ratio was used for higher or lower concentrations. 
Cells were either transfected with ppp-RNA, generated as described in section 4.4.4 or with 
the double-stranded control RNA (OH-RNA) purchased from Eurofins Genomics with the 
following sequence: 5´-GCG CUA UCC AGC UUA CGU A-3´ with and without 
dTdT-3´modification. 
Transfection medium: 
DMEM 
L-Glut (2 mM) 
1 % (v/v) FBS 
4.5 Statistical analysis 
Statistical analysis was performed using GraphPad PRISM 6.0 from GraphPad Software 
(USA). In vitro data are presented as mean and standard deviation (SD). In vivo data are 
presented as mean and standard error of the mean (SEM). Unpaired data were analyzed via 
ordinary one-way ANOVA followed by Tukey´s multiple comparisons tests and unpaired t test 
with Welch's correction, respectively. Paired data were analyzed using a paired t test. Data 
were considered statistically significant if p < 0.05. Survival analysis was depicted as 
Kaplan-Meier estimator. To compare survival distributions a log-rank test was performed. 
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5 Results 
The cytosolic helicase RIG-I serves as potential target for the development of an 
immunotherapy for the treatment of HCC (section 1.4.2). In order to investigate this 
hypothesis more closely in the context of this work, RIG-I expression first was assessed in 
murine and human HCC cell lines, as well as in human HCC tissue cores. The protein´s 
functionality was further examined in vitro. After having established two orthotopic mouse 
models of HCC, the efficacy of the ppp-RNA-based immunotherapy and its immune-
mediated effector functions were investigated in vivo. The underlying results are described in 
the following. 
5.1 RIG-I expression and regulation in human and murine HCC 
In order to evaluate RIG-I as target for a ppp-RNA-based immunotherapy in HCC, a set of 
239 tissues microarrays (TMA) of human HCC cores and three human (Huh7, Hep3B, 
HepG2) as well as three murine cell lines (RIL-175, Hep-55.1C, Hepa1-6) were investigated 
concerning RIG-I expression and regulation. 
 
 
Figure 3: RIG-I is expressed in human 
HCC tissue. RIG-I expression in tissue 
microarrays of 239 human HCC samples 
was analyzed via immunohistochemical 
staining. [A] RIG-I expression levels were 
defined through an expression score as 
depicted. [B] Frequency of RIG-I 
expression was determined using the 
RIG-I expression score (0 = unstained, 
1 = low expression, 2 = moderate 
expression, 3 = high expression). Analysis 
was performed in collaboration with Prof. 
Doris Mayr, Department of Pathology, 
LMU Munich. 
 
 
The TMA of human HCC biopsies were investigated for RIG-I expression via 
immunohistochemical staining and the strength of expression was classified through a score 
from 1 to 3 (0 = unstained/no expression, 1 = low expression, 2 = moderate expression, 
3 = high expression). 52 TMA were scored as 1, 130 as 2, 56 as 3 and only a single sample 
did not show any expression (Figure 3). RIG-I expression was confined to tumor cells rather 
than fibrotic tissue and the majority of samples exhibited moderate to strong RIG-I 
expression.  
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Figure 4: RIG-I is inducible in murine and human HCC cell lines. [A] Murine (Hep-55.1C, RIL-175, Hepa1-6) 
and [B] human (Huh7, Hep3B, HepG2) cells were stimulated with 1000 U/ml IFN-α for 48 h hours. RIG-I 
expression was assessed via western blot analysis. Untreated condition served as reference. Depicted is one 
representative experiment out of three. 
 
In order to test whether murine (Hep-55.1C, RIL-175, Hepa1-6) and human HCC (Huh7, 
Hep3B, HepG2) cell lines express RIG-I, protein levels were analyzed via western blot 
analysis in unstimulated as well as INF-α stimulated cells. Baseline expression levels of 
RIG-I were low, but readily induced by IFN stimulation (Figure 4). Next, RIG-I expression was 
studied in HCC cells via qRT-PCR and western blot after treatment with ppp-RNA and a 
respective control RNA (OH-RNA) (Figure 5). A specific upregulation of RIG-I was observed 
in murine and human HCC cell lines after transfection with ppp-RNA, with the exception of 
Huh7 cells, indicative of a positive type I IFN-mediated feed-back loop (Figure 5). 
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Figure 5: ppp-RNA treatment leads to RIG-I upregulation in murine and human HCC cells. Murine (RIL-175, 
Hep-55.1C, Hepa1-6) and human (Huh7, Hep3B, HepG2) HCC cells were transfected with 40 nM ppp-RNA and 
control RNA (OH-RNA), respectively. Untreated conditions served as additional controls. RIG-I expression [A] on 
mRNA level was investigated 24 h after transfection by qRT-PCR and [B], [C] on protein level 48 h after 
transfection via western blot analysis. qRT-PCR results are shown as mean of three experiments. Error bars 
represent standard deviation. Statistical analysis was performed via ordinary one-way ANOVA and Tukey´s 
multiple comparisons tests. Asterisks indicate p-values: ** < 0.01; *** < 0.001. Western blot analysis represents 
one representative experiment out of three. 
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5.2 Functional consequences of RIG-I activation in murine and 
human HCC cell lines 
As the treatment with ppp-RNA of murine and human HCC cells induced RIG-I expression in 
vitro (Figure 4 and Figure 5), functional consequences of the activation of this signaling 
pathway were investigated. To this end, downstream effects like MHC-I upregulation, IFN-ȕ 
induction, IP-10 secretion and cell death were analyzed. MHC-I was upregulated upon 
ppp-RNA stimulus in RIL-175 and Hep-55.1C cells, but not in Hepa1-6 cells, whereas IFN-ȕ 
and IP-10 were induced in all three murine cell lines. Furthermore, ppp-RNA treatment 
induced tumor cell death (Figure 6). Similar effects of ppp-RNA treatment were observed for 
human Hep3B and Huh7 cells: the transfection of cells with ppp-RNA led to the upregulation 
of HLA-I and IFN-ȕ and the secretion of IP-10. In addition, it significantly reduced tumor cell 
viability (Figure 7). 
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Figure 6: RIG-I signaling is functional in murine HCC cells. RIL-175, Hep-55.1C and Hepa1-6 cells were 
transfected with 40 nM ppp-RNA and 40 nM control RNA (OH-RNA), respectively. Untreated conditions served as 
additional controls. [A] Upregulation of MHC-I was analyzed 48 h after transfection via flow cytometry. [B] 
Induction of IFN-ȕ expression was assessed 24 h after transfection on mRNA level by qRT-PCR. [C] Secretion of 
IP-10 was detected 48 h after transfection in the cell culture supernatant via ELISA. [D] Cell death was analyzed 
48 h after transfection via Annexin V/PI staining and flow cytometry. Viable cells were defined as double negative 
population. Results are shown as mean of three experiments. Error bars represent standard deviation. Statistical 
analysis was performed via ordinary one-way ANOVA and Tukey´s multiple comparisons tests. Asterisks indicate 
p-values: *<0.05; ** < 0.01; *** < 0.001.  
 
 
Figure 7: RIG-I signaling is functional in human HCC cells. Huh7 and Hep3B cells were transfected with 40 
nM ppp-RNA or 40 nM control RNA (OH-RNA). Untreated conditions served as additional controls. [A] 
Upregulation of MHC-I was analyzed 48 h after transfection via flow cytometry. [B] Induction of IFN-ȕ expression 
was assessed 24 h after transfection on mRNA level by qRT-PCR. [C] Secretion of IP-10 was detected 48 h after 
transfection in the cell culture supernatant via ELISA. [D] Cell death was analyzed 48 h after transfection via 
Annexin V/PI staining and flow cytometry. Viable cells were defined as double negative population. Results are 
shown as mean of three experiments. Error bars represent standard deviation. Statistical analysis was performed 
via ordinary one-way ANOVA and Tukey´s multiple comparisons tests. Asterisks indicate p-values: *< 0.05; 
** < 0.01; *** < 0.001. 
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5.3 Establishing orthotopic HCC in vivo models 
In order to investigate the therapeutic effect of ppp-RNA-based immunotherapy, orthotopic 
murine HCC models were established. To this end, Hep-55.1C, RIL-175 or Hepa1-6 cells 
were injected into the left liver lobe of C57BL/6 mice. A tumor growth analysis was performed 
based on CT imaging and survival of tumor-bearing mice was monitored over 60 days. 
Injection of Hep-55.1C and RIL-175 cells into the liver led to steady tumor cell growth and 
resulted in tumor-related death, whereas Hepa1-6 cells only led to the establishment of a 
liver tumor in 3 out of 7 mice (Figure 8). Unreliable tumor take of Hepa1-6 cells was 
surprising, as this is a well-described HCC in vivo model in the literature (He et al., 2016; 
Kuang et al., 2013; Ma et al., 2014; Rao et al., 2016). 
 
Figure 8: RIL-175 and Hep-55.1C cells are suitable for HCC in vivo studies. RIL-175 (n = 6), Hep-55.1C 
(n = 7) or Hepa1-6 cells (n = 7) were orthotopically transplanted into the left liver lobe of C57BL/6 mice. 
[A] Exemplarily shown is the CT-based imaging of a RIL-175 tumor on indicated days after tumor inoculation. 
[B] Survival of mice with induced tumors is depicted as Kaplan-Meier curve. [C] Orthotopic tumor growth was 
monitored via CT and tumor volumes were calculated using ImageJ. CT analysis was performed in collaboration 
with Prof. Kirsten Lauber and Dr. Benjamin Stegen, Department of Radiation Oncology, LMU Munich. 
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5.4 In vivo ppp-RNA-based immunotherapy of HCC 
After having established two murine orthotopic HCC in vivo models (Hep-55.1C and 
RIL-175 cells) (Figure 8), the in vivo efficacy of RIG-I-based immunotherapy was assessed.  
5.4.1 Therapeutic efficacy 
In order to address how systemic ppp-RNA treatment affects tumor growth and survival of 
tumor-bearing mice, RIL-175 or Hep-55.1C cells were orthotopically induced in C57BL/6 
mice. After 5 days for tumor engraftment, mice were treated every 3-4 days with i.v. 
injections of ppp-RNA or a respective control RNA (OH-RNA). Survival of mice was 
monitored for up to 100 days. Therapy with ppp-RNA significantly prolonged median survival 
in the RIL-175 tumor model to 46 days as compared to 24 or 25 days in the control groups. 
In contrast, mice bearing Hep-55.1C-tumors did only marginally benefit from ppp-RNA 
therapy in comparison to untreated mice, but not in comparison to mice injected with control 
RNA (OH-RNA) (Figure 9, Table 1, Table 6). 
 
Figure 9: ppp-RNA immunotherapy significantly prolongs survival of RIL-175 tumor-bearing mice. 
[A] RIL-175 or [B] Hep-55.1C cells were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were 
treated with 50 µg ppp-RNA complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 5, 9, 12, 16, 19 and 
23 after tumor inoculation via i.v. injection or left untreated. Survival was monitored over 100 days and is depicted 
as Kaplan-Meier curve. P-values were calculated performing a log-rank test and are listed in Table 1 (RIL-175 
tumor-bearing mice: n (untreated) = 9; n (OH-RNA) = 10; n (ppp-RNA) = 10. Hep-55.1C tumor-bearing mice: 
n (untreated) = 4; n (OH-RNA) = 4; n (ppp-RNA) = 5). 
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Table 1: Statistic outcome of survival analysis of RIL-175 and Hep-55.1C tumor-bearing mice after 
ppp-RNA therapy. Listed p-values were calculated via log-rank test of survival analysis depicted in Figure 9. 
Cell line Parameter p-value 
 untreated vs. OH-RNA 0.7102 
RIL-175 untreated vs. ppp-RNA < 0.0001 
 OH-RNA vs. ppp-RNA < 0.0001 
 untreated vs. OH-RNA 0.0725 
Hep-55.1C untreated vs. ppp-RNA 0.0318 
 OH-RNA vs. ppp-RNA 0.7063 
 
5.4.2 Immune monitoring during ppp-RNA therapy 
It could be demonstrated that systemic ppp-RNA treatment positively impacts the survival of 
mice bearing liver tumors (Figure 9, Table 1). The immunological effects induced by this 
therapy, such as cytokine induction and immune cell activation, were further examined. 
5.4.2.1 Orthotopic Hep-55.1C model 
Hep-55.1C tumors were orthotopically induced in the left liver lobe of C57BL/6 mice. Mice 
were treated with repeated injections of ppp-RNA intravenously. The systemic application of 
ppp-RNA significantly increased plasma levels of the pro-inflammatory chemokine IP-10 
(Figure 10). OH-RNA also induced IP-10 production, albeit lower levels, pointing to a 
TLR-mediated off-target effect of the RNA (Ellermeier et al., 2013). The systemic ppp-RNA 
treatment led to the influx of CD8+ T cells in the tumor tissue and to a slight reduction of 
splenic NK cells. Changes in the numbers of CD4+ T cells were not statistically significant 
(Figure 11). Furthermore, NK cells in the tumor and spleen showed increased expression 
levels of the activation marker CD69 (Figure 12). 
 
 
Figure 10: Systemic ppp-RNA therapy increases IP-10 
plasma levels in tumor-bearing mice. Hep-55.1C tumors 
were induced orthotopically in the left liver lobe of 
C57BL/6 mice. Mice were treated with 50 µg ppp-RNA 
complexed to in vivo-jetPEI® or control RNA (OH-RNA) on 
day 5 after tumor inoculation via i.v. injection. Untreated mice 
served as control. Blood was drawn 4 h after ppp-RNA 
administration and IP-10 plasma levels were determined via 
ELISA. Results are shown as mean and error bars represent 
SEM. Statistical analysis was performed via ordinary one-way 
ANOVA and Tukey´s multiple comparisons tests (n = 4; 5; 5 
for untreated; OH-RNA; ppp-RNA, respectively). Asterisks 
indicate p-value: *** < 0.001. 
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Figure 11: Accumulation of T cells at the tumor site after systemic ppp-RNA immunotherapy. Hep-55.1C 
tumors were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were treated with 50 µg ppp-RNA 
complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 5, 9, 12, 16, 19 and 23 after tumor induction via 
i.v. injection. 12 h after the last ppp-RNA injection mice were sacrificed and spleens and tumors were explanted. 
Immune cell populations were analyzed via flow cytometry. CD4+ T cells were defined as CD45+CD3+CD4+, 
CD8+ T cells as CD45+CD3+CD4+, NK cells as CD45+CD3-NK-1.1+. Results are shown as mean and error bars 
represent SEM. Statistical analysis was performed using an unpaired t test with Welch's correction (tumor: n = 4; 
spleen: n = 5). Asterisk indicates p-value: * < 0.05. 
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Figure 12: Systemic ppp-RNA application leads to the activation of NK cells in tumor and spleen.  
Hep-55.1C tumors were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were treated with 50 µg 
ppp-RNA complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 5, 9, 12, 16, 19 and 23 after tumor 
induction via i.v. injection. 12 h after the last ppp-RNA injection mice were sacrificed and spleens and tumors 
were explanted. Expression of CD69 of immune cells was analyzed via flow cytometry. CD4+ T cells were defined 
as CD45+CD3+CD4+, CD8+ T cells as CD45+CD3+CD4+, NK cells as CD45+CD3-NK-1.1+. Results are shown as 
mean and error bars represent SEM. Results are shown as mean and error bars represent SEM. Statistical 
analysis was performed using an unpaired t test with Welch's correction (tumor: n = 4; spleen: n = 5). Asterisk 
indicates p-value: * < 0.05. 
 
5.4.2.2 Orthotopic RIL-175 model 
RIL-175 liver tumors were orthotopically induced in C57BL/6 mice and mice were 
systemically treated with repeated injections of ppp-RNA. The systemic ppp-RNA therapy did 
not lead to a significant increase of T cells and NK cells at the tumor site or in the spleen. 
However, CD8+ T cells were slightly increased at the tumor site after treatment with 
therapeutic RNA in comparison to control groups, however, the difference lacked statistical 
significance (Figure 13). Despite strong cytokine induction (Figure 20), only activation of 
NK cells, but not of CD4+ and CD8+ T cells, could be observed at the tumor site in 
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comparison to the control group upon ppp-RNA therapy, as assessed by upregulation of the 
early activation marker CD69 and FasL (Figure 14). Furthermore, RIG-I-based therapy 
induced activation of CD8+ T cells, NK cells and CD4+ T cells in the spleen (Figure 15). 
 
Figure 13: Quantitative analysis of immune cell populations in tumor tissue and spleen after systemic 
ppp-RNA immunotherapy. RIL-175 tumors were induced orthotopically in the left liver lobe of C57BL/6 mice. 
Mice were treated with 50 µg ppp-RNA complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 10 and 
14 after tumor induction via i.v. injection. Untreated mice served as control. 12 h after the last ppp-RNA injection 
mice were sacrificed and tumors were explanted. Expression of CD69 and FasL by immune cells was analyzed 
via flow cytometry. CD4+ T cells were defined as CD45+CD3+CD4+, CD8+ T cells as CD45+CD3+CD4+, NK cells 
as CD45+CD3-NK-1.1+. Results are shown as mean and error bars represent SEM. Statistical analysis was 
performed via ordinary one-way ANOVA and Tukey´s multiple comparisons tests (n = 5 mice per group). 
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Figure 14: Systemic ppp-RNA application leads to the activation of NK cells at the tumor site. RIL-175 
tumors were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were treated with 50 µg ppp-RNA 
complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 10 and 14 after tumor induction via i.v. injection. 
Untreated mice served as control. 12 h after the last ppp-RNA injection mice were sacrificed and tumors were 
explanted. Expression of CD69 and FasL by immune cells was analyzed via flow cytometry. CD4+ T cells were 
defined as CD45+CD3+CD4+, CD8+ T cells as CD45+CD3+CD4+, NK cells as CD45+CD3-NK-1.1+. Results are 
shown as mean and error bars represent SEM. Statistical analysis was performed via ordinary one-way ANOVA 
and Tukey´s multiple comparisons tests (n = 5 mice per group). Asterisks indicate p-values: * < 0.05; **< 0.01. 
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Figure 15: ppp-RNA immunotherapy leads to the activation of splenic T cells and NK cells. RIL-175 tumors 
were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were treated with 50 µg ppp-RNA 
complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 10 and14 after tumor induction via i.v. injection. 
Untreated mice served as control. 12 h after the last ppp-RNA injection mice were sacrificed and spleens were 
explanted. Expression of CD69 and FasL by immune cells was analyzed via flow cytometry. CD4+ T cells were 
defined as CD45+ CD3+ CD4+, CD8+ T cells as CD45+ CD3+ CD4+, NK cells as CD45+ CD3- NK-1.1+. Results are 
shown as mean and error bars represent SEM. Statistical analysis was performed via ordinary one-way ANOVA 
and Tukey´s multiple comparisons tests (n = 5 mice per group). Asterisks indicate p-values: * < 0.05; **< 0.01. 
 
46 
Results 
5.4.3 Toxicity of ppp-RNA therapy 
To investigate potential toxic hematological side effects caused by the systemic ppp-RNA 
immunotherapy, the distribution of immune cell populations in the blood was examined. The 
relative frequency of T cells, NK cells, NKT cells and B cells in the blood was significantly 
reduced 24 h after RNA injection and recovered after 48 h, whereas NK cell levels appeared 
to be slightly elevated at this time point. Conversely, the levels of blood monocytes were 
significantly increased 24 h after injection of ppp-RNA and decreased after 48 h (Figure 
16 A). To assess kidney or liver damage induced by the ppp-RNA immunotherapy, plasma 
levels of urea, GOT and GPT were analyzed. No significant differences between untreated 
mice and mice treated with control RNA or ppp-RNA could be observed regarding GOT and 
GPT levels (Figure 16 B). 
 
Figure 16: ppp-RNA immunotherapy does not cause long lasting severe adverse effects. [A] Frequency of 
T (CD45+CD3+), NK (CD45+CD3-NK-1.1+), NKT (CD45+CD3+NK-1.1+), B cells (CD45+CD19+) and monocytes 
(CD45+CD14+) were determined via flow cytometry 0 h, 24 h and 48 h after i.v. injection of 50 µg ppp-RNA 
complexed to in vivo-jetPEI® in healthy non-tumor bearing mice. Results are shown as mean and error bars 
represent SEM. Statistical analysis was performed using a paired t test (n = 8 for 0 h and n = 9 for 24 and 48 h, 
respectively). [B] Hepa1-6 tumors were induced orthotopically in the left liver lobe of C57BL/6 mice. Mice were 
treated with 50 µg ppp-RNA complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 5, 9, 12, 16, 19 and 
23 after tumor induction via i.v. injection. Urea, GOT and GPT plasma values were determined 12 h after the last 
injection. Results are shown as mean and error bars represent SEM. Statistical analysis was performed via 
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ordinary one-way ANOVA and Tukey´s multiple comparisons tests (n = 4 for untreated; n = 7 for OH-RNA and 
ppp-RNA, respectively). Asterisks indicate p-values: * < 0.05; ** < 0.01; *** < 0.001. 
 
5.4.4 Immune-mediated effector mechanisms 
In order to address the role of the immune system for the therapeutic efficacy of the 
ppp-RNA-based therapy, RIL-175 tumors were orthotopically induced in immune-deficient 
NOD-scid IL2Rγnull (NSG) mice and treated with repeated injections of ppp-RNA 
intravenously starting on day 5 after tumor induction. Mice treated with the therapeutic RNA 
had no benefit concerning survival in comparison to the untreated group (Figure 17). 
Interestingly, mice succumbed much quicker to the tumor challenge than wild-type mice (see 
Figure 9). 
 
 
Figure 17: The immune system plays a critical role for 
the therapeutic efficacy of ppp-RNA-based therapy. 
RIL-175 tumors were orthotopically induced in the left liver 
lobe of NOD-scid IL2Rγnull mice. Mice were treated with 
50 µg ppp-RNA complexed to in vivo-jetPEI® or control 
RNA (OH-RNA) on days 5, 9 and 12 after tumor induction 
via i.v. injection. Survival was monitored and is depicted as 
Kaplan-Meier curve; p-values were calculated performing a 
log-rank test (n = 5 mice per group). 
 
 
5.4.4.1 Influence of T and NK cells on therapeutic efficacy 
To narrow down which immune cell population is involved in the therapeutic mode of action, 
CD4+ T cells, CD8+ T cells or NK cells were depleted via anti-CD4, anti-CD8 or anti-NK-1.1 
antibody administration, respectively, in RIL-175 tumor-bearing mice prior to ppp-RNA 
injections. The depletion of these immune cell populations did not lead to significantly 
different IP-10 plasma levels in comparison to mice injected with the respective isotype (IgG) 
prior to ppp-RNA (Figure 18). Interestingly, the therapeutic effect was completely abolished 
after the depletion of CD8+ T cells, whereas the depletion of NK cells had no impact on the 
therapeutic efficacy (Figure 18, Table 2). Depletion of and CD4+ also decreased therapeutic 
efficacy, however statistical significance was not reached (p = 0.07). 
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Figure 18: Therapeutic efficacy of ppp-RNA immunotherapy is CD8+ and CD4+ T cell dependent. RIL-175 
tumors were orthotopically induced in the left liver lobe of C57BL/6 mice. Mice were treated with 50 µg ppp-RNA 
complexed to in vivo-jetPEI® or control RNA (OH-RNA) on days 5, 9, 12, 16, 19 and 23 after tumor inoculation via 
i.v. injection. α-CD8, α-CD4 and α-NK-1.1 depleting antibodies or respective isotype control (IgG) were 
administered in addition via i.p. injection 24 h prior to RNA injection. [A] Blood was drawn 24 h after injection of 
depleting antibodies and immune cell populations were analyzed via flow cytometry. Plots shown were gated on 
CD45+ cells. Depleted immune cell populations are highlighted in red. Depicted is one representative data set 
(n = 5 mice per group; n = 4 for ppp-RNA + α-CD4). [B] Blood was drawn 4 h after the fifth therapy and IP-10 
plasma levels were determined via ELISA. Results are shown as mean and error bars represent SEM. Statistical 
analysis was performed via ordinary one-way ANOVA and Tukey´s multiple comparisons tests (n(untreated) = 5; 
n(ppp-RNA + IgG) = 5; n(ppp-RNA + α-CD8) = 3; n(ppp-RNA + α-CD4) = 4; n(ppp-RNA + α-NK) = 5). Asterisks 
indicate p-value: *** < 0.001. [C] Survival was monitored for up to 100 days and is depicted as Kaplan-Meier 
curve; p-values were calculated performing a log-rank test and are listed in Table 2 (n = 5 mice per group; n = 4 
for ppp-RNA + α-CD4). 
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Table 2: Statistic outcome of survival analysis after depletion of CD8+, CD4+ and NK cells in RIL-175 
tumor-bearing mice treated with ppp-RNA immunotherapy. Listed p-values were calculated via log-rank test 
of survival analysis depicted in Figure 18. 
Parameter p-value 
ppp-RNA + IgG vs. untreated 0.0116 
ppp-RNA + IgG vs. ppp-RNA + a-CD8 0.0136 
ppp-RNA + IgG vs. ppp-RNA + a-CD4 0.0712 
ppp-RNA + IgG vs. ppp-RNA + a-NK 0.9972 
 
5.4.4.2 Analysis of treatment-induced immunological memory response 
Mice that survived the tumor challenge due to ppp-RNA treatment longer than 100 days were 
rechallenged with the same tumor cells subcutaneously in order to investigate a potential 
formation of an immunological memory. All of the rechallenged mice rejected the tumor while 
naïve control mice all developed a tumor (Figure 19). 
 
 
Figure 19: ppp-RNA immunotherapy mediates 
immunological memory. Surviving mice of prior 
experiments that had rejected their orthtotopic RIL-175 
tumors upon ppp-RNA treatment (see Figure 18, Figure 
20, Figure 22) were rechallenged with tumor cells s.c. after 
at least 100 days following the primary tumor challenge 
(n = 8). Naїve mice (n = 5) served as control. Tumor 
growth curves of individual mice are shown. 
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5.4.4.3 Influence of systemic MAVS and type I IFN signaling on treatment 
response 
To closer examine the signaling pathway triggering the therapeutic efficacy of the 
ppp-RNA-based immunotherapy, the influence of systemic RLH and type I IFN signaling was 
investigated in vivo. To this end, Mavs-/- and Ifnar1-/- mice on C57BL/6 background were 
orthotopically induced with RIL-175 tumors and treated with repeated i.v injections of 
ppp-RNA. Studies revealed a moderate decrease of IP-10 plasma levels after ppp-RNA 
treatment in MAVS- and a significant decrease in IFNAR1-deficient mice, compared to 
wild-type mice. Of note, compared to wild-type mice, survival was not different in MAVS- and 
IFNAR1-deficient mice, indicating that systemic MAVS and IFNAR signaling is dispensable 
for the treatment efficacy (Figure 20, Table 3 and Table 4). 
 
Figure 20: Therapeutic mode of action of ppp-RNA therapy is independent of systemic MAVS and IFNAR 
signaling. RIL175 tumors were orthotopically induced in the left liver lobe of C57BL/6 (Wt), Mavs-/- and Ifnar1-/- 
mice. Hosts were either treated with 50 µg ppp-RNA complexed to in vivo-jetPEI® on days 5, 9, 12, 16, 19 and 23 
after tumor inoculation via i.v. injection or left untreated. [A] 4 h after the first therapy blood was drawn and IP-10 
plasma levels were analyzed via ELISA. Results are shown as mean and error bars represent SEM. Statistical 
analysis was performed via ordinary one-way ANOVA and Tukey´s multiple comparisons tests; n = 4-5 mice per 
group. Asterisks indicate p-values: ** < 0.01; *** < 0.001. [B] Survival was monitored over 100 days and is 
depicted as Kaplan-Meier curve. P-values were calculated performing a log-rank test and are listed in Table 3. 
Median survival was calculated and is listed in Table 4 (n = 4-5 mice per group).  
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Table 3: Statistic outcome of survival analysis of RIL-175 tumor-bearing C57BL/6 mice with Mavs-/- or 
Ifnar1-/- background treated with ppp-RNA immunotherapy. Listed p-values were calculated via log-rank test 
of survival analysis depicted in Figure 20. 
Genotype Parameter p-value 
Wt untreated vs. ppp-RNA 0.0015 
Mavs-/-  untreated vs. ppp-RNA 0.0027 
Ifnar1-/-  untreated vs. ppp-RNA 0.0072 
Wt vs. Mavs-/- ppp-RNA vs. ppp-RNA 0.7462 
Wt vs. Ifnar1-/- ppp-RNA vs. ppp-RNA 0.4914 
Mavs-/- vs. Ifnar1-/- ppp-RNA vs. ppp-RNA 0.5852 
 
Table 4: Median survival of RIL-175 tumor-bearing C57BL/6 mice with Mavs-/- or Ifnar1-/- background 
treated with ppp-RNA immunotherapy. Listed median survival was calculated from survival analysis depicted in 
Figure 20.  
Genotype Treatment Median survival [d] 
Wt untreated 21 
 ppp-RNA 49 
Mavs-/- untreated 27 
 ppp-RNA 42 
Ifnar1-/- untreated 24 
 ppp-RNA 37 
 
5.4.4.4 Combination of ppp-RNA therapy with checkpoint inhibition 
In the previous experiments it was shown that T cells are crucially involved in the mode of 
action of the RIG-I based immunotherapy. As PD-L1 is an IFN-stimulated gene and therefore 
likely upregulated after ppp-RNA stimulation, blocking of the PD-1/PD-L1 axis may result in a 
stronger anti-tumoral T cell response. Murine (RIL-175, Hep-55.1C, Hepa1-6) and human 
(Huh7, Hep3B) HCC cells were analyzed for their expression of PD-L1 after transfection with 
ppp-RNA. The analysis showed that PD-L1 expression is significantly increased in all the 
investigated tumor cell lines after ppp-RNA stimulation (Figure 21).  
In order to try to improve therapy´s efficacy, ppp-RNA was combined with repeated injections 
of an α-PD-1 blocking antibody. The analysis revealed that mice strongly benefited from the 
combination of ppp-RNA and checkpoint inhibition in comparison to ppp-RNA-treatment 
alone in the RIL-175 model with 60 % of mice showing complete tumor control up to 100 
days, but not in the Hep-55.1C model (Figure 22, Table 5 and Table 6). 
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Figure 21: Stimulation of tumor cells with ppp-RNA induces PD-L1 expression. [A] Murine and [B] human 
HCC cells were transfected with 40 nM ppp-RNA, 40 nM control RNA (OH-RNA) or left untreated. PD-L1 
expression was analyzed 48 h later via flow cytometry. Results are shown as mean of three (murine) and four 
(human) experiments, respectively. Error bars represent standard deviation. Statistical analysis was performed 
via ordinary one-way ANOVA and Tukey´s multiple comparisons tests. Asterisks indicate p-values: * < 0.05; 
** < 0.01; *** < 0.001. 
 
 
Figure 22: Combination of ppp-RNA therapy with checkpoint inhibition increases median survival of 
RIL-175 tumor-bearing mice. [A] RIL-175 or [B] Hep-55.1C tumors were induced orthotopically in the left liver 
lobe of C57BL/6 mice. Mice were treated with 50 µg ppp-RNA complexed to in vivo-jetPEI® or control RNA 
(OH-RNA) on days 5, 9, 12, 16, 19 and 23 after tumor inoculation via i.v. injection. 100 µg blocking α-PD-1 
antibody were administered i.p. on days 4, 11 and 18. Survival was monitored over 100 days and is depicted as 
Kaplan-Meier curve; p-values were calculated performing a log-rank test and are listed in Table 5. Median survival 
of RIL-175 tumor-bearing mice was calculated and is listed in Table 6 (RIL-175 tumor-bearing mice: n(untreated) 
= 9; n(OH-RNA) = 10; n(ppp-RNA) = 10; n (α-PD-1) = 5; n(α-PD-1 + ppp-RNA) = 5. Hep-55.1C tumor-bearing 
mice: n(untreated) = 4; n(OH-RNA) = 4; n(ppp-RNA) = 5; n (α-PD-1) = 5; n(α-PD-1 + ppp-RNA) = 5). 
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Table 5: Statistic outcome of RIL-175 and Hep-55.1C tumor-bearing C57BL/6 mice treated with ppp-RNA in 
combination with checkpoint inhibition. Listed p-values were calculated via log-rank test of survival analysis 
depicted in Figure 22. 
Cell line Parameter p-value 
 untreated vs. OH-RNA 0.7102 
 untreated vs. ppp-RNA < 0.0001 
RIL-175 untreated vs. α-PD-1 0.0943 
 OH-RNA vs. ppp-RNA < 0.0001 
 ppp-RNA vs. α-PD-1 + ppp-RNA 0.0604 
 untreated vs. OH-RNA 0.0725 
 untreated vs. ppp-RNA 0.0318 
Hep-55.1C untreated vs. α-PD-1 0.0882 
 OH-RNA vs. ppp-RNA 0.7063 
 ppp-RNA vs. α-PD-1 + ppp-RNA 0.7146 
 
Table 6: Median survival of RIL-175 tumor-bearing C57BL/6 mice treated with ppp-RNA in combination 
with checkpoint inhibition. Listed median survival was calculated from survival analysis depicted in Figure 22. 
Treatment Median survival [d] 
untreated 25 
OH-RNA 24 
ppp-RNA 46 
α-PD-1 28 
ppp-RNA + α-PD-1 undefined 
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6 Discussion 
Hepatocellular carcinoma (HCC) ranks amongst the most aggressive cancer types with an 
overall 5-year survival rate of only 17 % (Siegel et al., 2015). In most cases, HCC is 
diagnosed at late stage and surgical excision or local ablative destruction of the tumor is not 
possible. In some cases, liver transplantation is another treatment option. However, the 
growing number of potential recipients is much higher than the number of available organs 
(reviewed in Slotta et al., 2015). The development of new drugs, acting at the molecular 
level, has improved treatment options of HCC. The discovery of targeted therapies, by 
blocking specific receptors, such as VEGFR (vascular endothelial growth factor receptors) 
and c-Met, and their downstream signaling, prevent or at least delay tumor growth with 
benefits regarding survival time (reviewed in Li and Wang, 2016; Zhang and Finn, 2016). 
Also, in the field of immunotherapy, there are therapeutic strategies that have already made 
it into clinical trials. While these new approaches, for example based on cancer vaccines and 
checkpoint inhibitors, may look promising, they still need to be fully explored (reviewed in 
Buonaguro et al., 2013; Greten et al., 2015; Hong et al., 2015). However, there is a strong 
medical need for developing new therapeutic interventions. The scientific study of an 
immunotherapy targeting receptors of the innate immune system is subject of this work. It is 
based on years of exploration of the cytosolic helicase RIG-I as target for cancer 
immunotherapy and recent findings of research linked with RIG-I expression in HCC. 
6.1 RIG-I signaling in murine and human HCC cell lines 
The ubiquitously expressed cytosolic helicase RIG-I belongs to the family of RLH, which play 
a key role in the first line of defense against pathogenic RNA viruses. Its activation triggers 
the innate and the adaptive immune system by inducing a type I IFN response and the 
release of several pro-inflammatory cytokines (reviewed in Iwasaki and Medzhitov, 2010; 
Takeuchi and Akira, 2008). In addition, different working groups demonstrated that the 
activation of RLH, imitating a viral infection, via in vitro-transcribed or synthetic double 
stranded RNA induces the intrinsic mitochondrial and the extrinsic CD95-mediated apoptotic 
pathway, respectively (Besch et al., 2009; Duewell et al., 2014). This immunogenic form of 
apoptosis leads to enhanced antigen presentation by dendritic cells and activation of tumor-
directed T cells (Duewell et al., 2014). RIG-I has already been investigated as potential target 
in cancer research, including melanoma, pancreatic cancer, lung cancer, breast cancer and 
HCC (Duewell et al., 2014; Ellermeier et al., 2013; Funk, 2018; Lazić, β017; Poeck et al., 
2008). Due to the autocrine signaling, which is caused upon RIG-I activation, agonists of 
RIG-I would provide one possible treatment option in the setting of cancer therapy (Kang et 
al., 2004). In addition, the technical possibility to convert 5´-ppp-RNA into 5´-ppp-siRNA 
gives promising results to combine RIG-I activation and the silencing of specific oncogenes 
via RNAi within one molecule (Ellermeier et al., 2013; Poeck et al., 2008). 
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In order to address the idea of a RIG-I-based immunotherapy in HCC, the expression of the 
cytosolic helicase and its functionality was first assessed in human and murine HCC cell 
lines (sections 5.1 and 5.2). To this end 239 tissue micro arrays (TMA) of human HCC 
samples were tested positive for the expression of RIG-I, whereby the expression levels 
were categorized into three different levels: low, moderate and high (Figure 3). Further in 
vitro experiments confirmed that RIG-I signaling is functional in murine (Hep-55.1C, RIL-175, 
Hepa1-6) and human (Huh7, Hep3B) HCC cell lines, as stimulation with IFN-α and ppp-RNA 
increased the expression of RIG-I on mRNA and protein level (Figure 5). The transfection of 
the different cell lines led to the induction of IFN-ȕ and subsequent upregulation of 
IFN-stimulated genes like MHC-I/HLA, RIG-I itself and IP-10 (Figure 5, Figure 6 and Figure 
7). Thus, RIG-I signaling leads to its own amplification in a type I IFN-dependent positive 
feedback loop (Kang et al., 2004; Schmidt et al., 2009). However, there was no MHC-I 
expression detected on the surface of Hepa-1-6 cells, neither with nor without transfection of 
ppp-RNA (Figure 6). As the cell line was originally generated from the C57L-mouse strain, 
and not from C57BL/6-mice (origin of RIL-175 and Hep-55.1C cells) the haplotype of this cell 
line (H-2kbc) differs from the one with C57BL/6-background (H-2kb) (BioLegend). This may be 
the reason why there was no expression of MHC-I detected with commercially available 
mAb. Another reason may be that the cell line is impaired in MHC-I expression or signaling, 
respectively. The reduction of the cell viability after stimulation of the HCC cells with 
ppp-RNA results from the induction of the intrinsic apoptotic pathway (Figure 6 and Figure 7). 
These findings are in line with Besch et al. (2009), who first showed that endogenous 
apoptosis cannot only be triggered by RIG-I signaling via the induction of type I IFN, but also 
be initiated IFN-independently upon ppp-RNA stimulation of tumor cells. Together, these 
findings indicate that RIG-I is expressed and functional in HCC, which is in line with previous 
work in our lab and sets the basis for in vivo therapy studies for the development of 
ppp-RNA-based immune therapeutics (Funk, 2018; Lazić, β017). 
6.2 Establishment of suitable HCC mouse models 
After having demonstrated that the RIG-I signaling pathway is functional in murine and 
human HCC cell lines in vitro (sections 5.1 and 5.2) the efficacy of the ppp-RNA-based 
immunotherapy was to be further tested in vivo. To this end, the model of choice was the 
orthotopic transplantation of murine HCC cells in the left liver lobe of syngeneic C57BL/6 
mice (section 5.3). Implantation models are frequently used for the pre-clinical investigation 
of new drugs with the advantage of creating a closer setting to human cancer regarding the 
tumor microenvironment and morphology of the tumor than in subcutaneous models 
(reviewed in Bibby, 2004; Khanna and Hunter, 2005; Leenders et al., 2008). In addition, 
using immune competent mice provides an intact immune system serving as a proof of 
concept for a therapy´s efficacy and mode of action. It has also been described as a model 
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being suitable for testing immune checkpoint inhibitors in an experimental in vivo-setting, as 
tumor cells and immune cells can fully interact with each other. However, tumor development 
is neither based on chronic inflammation due to rapid tumor growth nor on mutational load 
(reviewed in Sanmamed et al., 2016), making syngeneic models less suitable for therapies 
acting on the onset of tumor development and for drugs targeting specific mutations. 
The orthotopic transplantation of Hep55-1.C and RIL-175 cells led to steady tumor cell 
growth and resulted in tumor-related death of mice. The establishment of a Hepa1-6 HCC in 
vivo model was not successful, as only 3 out of 7 transplanted mice developed a liver tumor 
(Figure 8). One reason therefore may be the discrepancies of the haplotype between the 
transplanted cells (Hepa1-6: C57L-mouse strain) and the host (C57BL/6 mouse strain). In a 
strict sense, the Hepa1-6 model is not syngeneic with the C57BL/6 mouse strain. Thus, 
scientific publications using this murine HCC model should be interpreted with caution. 
6.3 Therapeutic efficacy and immune stimulatory potential of the 
RIG-I-based immunotherapy 
HCC is characterized by a pronounced immunosuppression due to high levels of 
immunosuppressive cytokines, such as TGF-ȕ and IL-10, impaired antigen presentation and 
accumulation of regulatory T cells and myeloid derived suppressor cells (reviewed in Hato et 
al., 2014; Makarova-Rusher et al., 2015). Recent studies implicate lymphocyte infiltration as 
prognostically favorable pointing out a role for CD8+ T cells in tumor control (Fatourou and 
Koskinas, 2009; Ikeguchi et al., 2004; Vesely et al., 2011). For an efficient immunotherapy it 
is therefore important to overcome tumor-promoting immunosuppression by targeted 
activation of immune cells. In order to investigate RIG-I as potential target for HCC 
immunotherapy in vivo, the efficacy of the therapeutic RNA and its immune stimulatory 
potential were investigated using the RIL-175 and Hep-55.1C HCC mouse models (sections 
5.4.1. and 5.4.2). The systemic ppp-RNA therapy of RIL-175 tumor-bearing mice significantly 
prolonged survival in comparison to the respective control groups. In contrast, mice with 
Hep-55.1C tumors did not benefit from the RIG-I-based immunotherapy (Figure 9, Table 1). 
Similar findings as in the RIL-175 in vivo model have been reported for models of melanoma 
and pancreatic carcinoma. Poeck et al. (2008) could show, that treatment of mice with 
subcutaneous B16-tumors significantly decelerated tumor growth. In addition, systemic 
treatment with ppp-RNA of mice with orthotopic Panc-02 tumors significantly prolonged 
survival of tumor-bearing mice (Ellermeier et al., 2013).  
The immunological effects induced by the ppp-RNA-based immunotherapy were further 
examined, also focusing on the difference between both in vivo models. The systemic 
injection of the therapeutic RNA significantly increased IP-10 plasma levels (Figure 10 and 
Figure 20) indicating an intact RIG-I signaling pathway (Schmidt et al., 2009). In addition, 
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ppp-RNA therapy led to a significant accumulation of CD8+ T cells at the tumor site. In this 
regard a positive trend could also be observed for CD4+ T cells (Figure 11). Furthermore, the 
ppp-RNA´s potential to induce an immune response by assessing the upregulation of the 
early activation marker CD69 and FasL, the ligand of the death receptor CD95 (Fas), on 
T cells and NK cells could be demonstrated. FasL is expressed on the surface of T cells after 
its activation and triggers the extrinsic apoptosis upon binding to CD95 on target cells 
(reviewed in O'connell et al., 1996). As CD95 is upregulated by tumor cells upon ppp-RNA 
treatment and its ligand, FasL, is upregulated on T and NK cells, FasL-mediated killing is 
likely an effector mechanism induced by this therapy. Activated NK cells were observed in 
the spleen and in the tumor of Hep-55.1C tumor-bearing mice (Figure 12). In the RIL-175 
HCC model, activated CD8+ T cells, CD4+ T cells (in respect to CD69 upregulation) and 
NK cells in the spleen, as well as activated NK cells at the tumor site could be detected after 
ppp-RNA immunotherapy (Figure 14 and Figure 15). These results clearly point towards an 
immune mediated tumor control, which was clearly demonstrated in immune-compromised 
NOD-scid IL2Rγnull mice (Figure 17). 
The mode of action of the ppp-RNA immunotherapy was further studied evaluating the role of 
individual immune cell populations (section 5.4.4). The anti-tumor efficacy was CD4+ and 
CD8+ T cell-dependent, whereas NK cells were dispensable for the therapeutic effect (Figure 
17 and Figure 18). In comparison, Poeck et al. (2008) found that the efficacy of ppp-RNA 
therapy is solely NK- and not CD8+ T cell-dependent in a B16-based melanoma mouse 
model. It was further shown that treatment with ppp-RNA induces a protective immunological 
memory linking innate and adaptive immunity, as shown by complete tumor rejection in 
rechallenge experiments (Figure 19).  The distinct role of T cells regarding the mechanism of 
action could be further investigated in a setting using adoptive T cell transfer in future 
experiments. Thereby CD4+ and CD8+ T cells of tumor-bearing mice, which were treated with 
ppp-RNA, could be transferred into naïve mice before tumor transplantation. By assessing 
the tumor growth in these mice it would be possible to gain further insights into the temporal 
dynamics and the interplay of these two cell types.The molecular mechanism of action was 
further demonstrated to be independent of systemic MAVS and IFNAR signaling using 
respective knockout (KO) mice, hinting towards a tumor cell-intrinsic RIG-I signaling 
response (Figure 20, Table 3). The median survival of Ifnar1-/- mice, and also of Mavs-/- mice, 
was not significantly reduced after ppp-RNA therapy in comparison to treated wild-type mice 
(Table 4). As endogenous IFN-α is essential for tumor surveillance and it has been already 
reported that mice with systemic Ifnar1 KO are more susceptible for tumor growth, a 
decreased median survival of untreated Ifnar1-/- mice in comparison to Wt mice would have 
been expected (Picaud et al., 2002). Maybe the initial tumor load was too high and 
differences between the two mouse strains could not be observed. Particularly surprising 
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were the results regarding the Ifnar1-/- mice, as APC, besides NK cells, need type I IFN for 
proper cross-priming of CD8+ T cells (Diamond et al., 2011; Fuertes et al., 2011; Fuertes et 
al., 2013). As CD8+ T cells seemed to be vitally important for the therapy´s effectiveness 
(section 5.4.4.1), the CD8+ T cell depletion experiments should be repeated in mice lacking 
IFNAR1 to confirm these findings. However, a significant difference in regards to the 
decrease of IP-10 plasma levels could be observed after ppp-RNA therapy from Mavs-/- to 
Ifnar1-/- mice, indicating that the induction of IP-10 in the plasma mainly depends on systemic 
IFNAR and also to some extent on systemic MAVS signaling (Figure 20). In what way the 
anti-tumoral effect of ppp-RNA therapy is mediated by intra-tumoral RIG-I signaling could be 
further assessed in an in vivo setting using RIG-I-deficient tumor cells transplanted into the 
respective knockout and wild-type mice, respectively. To further rule out that the therapy´s 
effect is IFN-α-dependent, the experiments could be performed using Ifnar1-/- tumor cells and 
Ifnar1-/- mice, respectively. However, in mouse models of pancreatic carcinoma, our working 
group found that systemic IFN-α therapy alone has no anti-tumoral efficacy (Hölz, 2018). 
In summary, the systemic treatment with the therapeutic ppp-RNA induced a profound 
immune response in both murine HCC tumor models, but the fundamental difference 
between the two models, which ultimately led to the different therapeutic results, could not be 
clarified in this work. Regarding the Hep-55.1C-based tumor model one may speculate about 
immune escape mechanisms such as an immunosuppressive microenvironment mediated by 
Treg and tumor-associated macrophages and the expression of immunosuppressive 
molecules such as PD-L1, as well as a defect in antigen presentation (reviewed in Beatty 
and Gladney, 2015). The resistance to apoptosis may also be taken into account (reviewed 
in Igney and Krammer, 2002). The given results point towards an intra-tumoral RIG-I 
signaling response (section 5.4.4.3). One point here to consider is the vascularization grade 
of Hep-55.1C and RIL-175 tumors regarding the proper delivery of the injected ppp-RNA into 
the tumor. This might be crucial for the therapy´s effectiveness. Going further, nucleic acid 
complexed to in vivo-jetPEI® is described to highly accumulate in the liver 24 h after 
intravenous injection (PerkinElmer Inc., 2013). In vivo-jetPEI®-Gal conjugated with 
galactose, the ligand of the asialoglycoprotein receptor (ASGP-R), which is highly expressed 
on hepatocytes, could be chosen for further experiments to improve the RNA´s proper 
delivery. In the context of tumor-targeted RNA delivery, one might also consider ppp-RNA 
loaded to nanoparticles, which are coated with liver homing-receptors. This is a smart 
approach to ensure appropriate drug delivery and to reduce off-target effects (reviewed in 
Kanasty et al., 2013; Reddy and Couvreur, 2011). Some approaches have already 
successfully made it into clinical trials showing promising results for advanced HCC and 
drug-resistant liver cancer (Gao et al., 2015; Merle et al., 2006). 
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6.4 Safety and tolerability of systemic ppp-RNA treatment 
In addition to the efficacy, safety and tolerability of the therapy were also investigated 
(section 5.4.3). It could be shown that repeated systemic treatment with ppp-RNA does not 
cause irreversible adverse events in vivo. There were no laboratory abnormalities in the sera 
of treated mice pointing towards an induced liver or kidney damage (Figure 16 B). A transient 
change in the composition of cells in the white blood cell count was observed. A significant 
decrease of relative numbers of peripheral T cells, NKT cells, NK cells and B cells occurred 
24 h after therapy, however, cell numbers recovered on the next day (Figure 16 A). An 
opposite effect in this setting was observed for monocytes (Figure 16 A). The latter may be 
due to the fact that only relative cell numbers were assessed. The effect of a transient 
leukopenia after ppp-RNA therapy was already reported by Ellermeier et al. (2013). The 
reason therefore is still unknown, but one may speculate that immune cells accumulate in 
secondary lymphoid organs after injection of the immune stimulatory RNA. In addition, 
leukopenia is a known side effect of therapy with IFN-α or IFN-, which is produced in large 
amounts during ppp-RNA treatment (Dusheiko, 1997; Goodin et al., 1995).  
A central question in the clinical setting remains the formulation of the therapeutic RNA. For 
this study the ppp-RNA was complexed to in vivo-jetPEI®, a polymer-based reagent that is 
also used in clinical trials. Nucleic acids formulated with this reagent and injected 
intravenously are reported to accumulate, among other sites, in the liver 24 h after 
administration (PerkinElmer Inc., 2013). One important point here to consider is that RIG-I 
signaling entails the considerable risk of a cytokine storm (Kaneda, 2013; Loo and Gale Jr, 
2011; Matsushima-Miyagi et al., 2012). It remains to be discussed, whether an intra-tumoral 
injection would be safer and potentially more effective. In this line, the intra-lesional 
administration of a RNA oligonucleotide-based RIG-I agonist complexed to PEI is currently 
under investigation in a phase I/II study in patients with injectable liver tumors or liver 
metastases (ClinicalTrials.gov, 2018c). 
6.5 Improving ppp-RNA-based immunotherapy  
Checkpoint inhibitors, such as mAb directed against PD-1 and PD-L1, are drugs braking 
tumor immune escape mechanisms that have revolutionized immunotherapy of cancer. PD-1 
is expressed by B cells, T cells and NK cells, whereas its ligand PD-L1 is expressed on 
various non-lymphoid tissue. Upon activation of T cells, the PD-1/PD-L1 axis acts as counter-
part of co-stimulatory molecules ensuring the equilibrium of immune activation and immune 
inhibition. T cells expressing PD-1 are inhibited from a proper anti-tumor response upon 
binding to its ligand PD-L1, which is expressed by tumor cells and myeloid cells in the tumor 
microenvironment (reviewed in Sharpe, 2017). Due to the fact that the PD-1/PD-L1 axis 
plays a crucial role in the immunosuppressive microenvironment of HCC (section 1.2), PD-1 
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blocking antibodies have recently made it into clinical HCC trials as single and combination 
therapy showing promising results in some patients (ClinicalTrials.gov, 2018a, 2018b; 
Truong et al., 2016). One rationale of this work was to examine the therapeutic potential of 
ppp-RNA immunotherapy in combination with checkpoint inhibition (5.4.4.4). In this context 
the impact of RIG-I signalling on the PD-1/PD-L1 axis was first assessed in vitro. Flow 
cytometric studies revealed that activation of RIG-I led to the expression of PD-L1 on tumor 
cells of murine and human HCC cell lines (Figure 21), providing a scientific rationale for 
combining ppp-RNA therapy with checkpoint inhibition. Combination therapy induced a 
synergistic therapeutic effect in RIL-175 tumor-bearing mice. Percent survival rates were 
highly prolonged in this in vivo model (Figure 22, Table 5 and Table 6). Interestingly, no 
significant effect was observed in the Hep-55.1C tumor model (Figure 22), although a strong 
induction of PD-L1 after ppp-RNA treatment was demonstrated for this cell line in vitro 
(Figure 21). Here again, the crucial difference between the two in vivo models in terms of the 
therapeutic efficacy could not be clarified. Possibly other immune checkpoints are dominantly 
inhibiting the infiltrating T cells in this tumor model. 
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7 Conclusion 
This study provides evidence that RIG-I is a novel target for HCC therapy. 239 human HCC 
tissue samples were analyzed for RIG-I expression by immunohistochemistry with almost 
100 % of the tumors staining positive. Moreover, functional RIG-I signaling was confirmed in 
different murine and human HCC cell lines stimulated with ppp-RNA in vitro, leading to 
type I IFN and IP-10 production, upregulation of MHC-I expression, as well as apoptotic cell 
death.  
In vivo efficacy of ppp-RNA-based therapy was demonstrated in mice bearing orthotopic 
RIL-175 liver tumors, significantly prolonging survival. The systemic application of the 
ppp-RNA was well tolerated, with a transient leukopenia being the only observed side effect 
at the tested dose. The lack of therapeutic efficacy in NSG mice, which are devoid of an 
intact immune system, and in mice that were depleted of CD4+ and CD8+ T cells point 
towards a T cell-mediated mechanism of action. Moreover, a sustained T cell memory was 
observed in successfully treated mice that were rechallenged with tumor cells, indicative of 
an immunogenic form of tumor cell death with T cell priming and T cell memory induction. 
The proposed mode of action of ppp-RNA-based immunotherapy in HCC is depicted in 
Figure 23. 
Interestingly, in this study therapeutic efficacy of ppp-RNA therapy was not affected in mice 
lacking MAVS, an adaptor molecule required for RIG-I signaling. This finding points towards 
a dominant role of tumor cell-intrinsic RIG-I signaling, as this pathway was still intact in tumor 
cells. Experiments with RIG-I-/MAVS-deficient tumor cells are currently performed in our 
group to further study the impact of tumor cell-intrinsic RIG-I signaling. Moreover, mice 
lacking the type I IFN receptor were still benefiting from ppp-RNA therapy, arguing that 
type I IFN is dispensable for treatment efficacy. 
Type I IFN signaling is known to upregulate the PD-1/PD-L1 axis thereby limiting overactive 
immune activation and potential tissue damage. From this perspective, the combination of 
RIG-I-based immunotherapy with α-PD-1 checkpoint inhibition is a promising rationale to 
enhance anti-tumor immune responses. In fact, combination therapy led to improved tumor 
control with complete tumor regression in 60 % of mice. No increase of toxicity was 
observed. Thus, combining ppp-RNA-based immune therapeutics with α-PD-1 mAb may 
offer new treatment options for patients suffering from HCC and deserves further preclinical 
and clinical investigation. 
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Figure 23: Proposed mode of action of ppp-RNA-based immunotherapy in HCC. Upon systemic ppp-RNA 
administration intra-tumoral RIG-I gets activated leading to the secretion of inflammatory cytokines and type I IFN 
as well as tumor cell death followed by DAMP (damage-associated molecular pattern) release. The secretion of 
inflammatory cytokines and type I IFN recruits antigen presenting cells (APC) which present processed tumor 
antigens to T cells via MHC-I leading to a tumor antigen specific T cell response. The secretion of type I IFN 
additionally leads to the activation of T cells indicated by the expression of the early activation marker CD69. 
Tumor cell killing is likely to be mediated via MHC-I/TCR and Fas/FasL interaction, respectively. The therapy 
mediates a strong immunological memory indicating proper T cell priming and clonal expansion. α-PD-1 
checkpoint inhibition improves the therapy´s efficacy by additional T cell activation. 
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9 Appendix 
9.1 Abbreviations 
actb Gene that encodes ȕ-actin 
AKT Protein kinase B 
ANOVA Analysis of variance 
ASGP-R Asialoglycoprotein receptor 
BSC Best supportive care 
BSA Bovine serum albumin 
CAR Chimeric antigen receptor 
CARD Caspase recruitment domain 
CD Cluster of differentiation 
cDNA Copy deoxyribonucleic acid 
cGas Cyclic GMP-AMP synthase 
CIK Cytokine-induced killer cells 
c-Met Cellular mesenchymal–epithelial transition 
CT Computed tomography 
CTD C-terminal regulatory domain 
CXCL10 C-X-C motif chemokine 10 (also known as IP-10) 
DAMP Damage-associated molecular pattern 
DC Dendritic cell 
ddx58 Gene that encodes RIG-I 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethylsulfoxide 
EDTA Ethylenediamine tetraacetic acid 
ELISA Enzym-linked immunosorbent assay 
EMA European Medicine Agency 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence activated cell sorter 
Fas Fas cell surface death receptor (also known as CD95) 
FasL Fas ligand 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FoxP3 Forkhead box P3 
GOT Glutamic oxaloacetic transaminase 
GPC3 Glypican 3 
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GPT Glutamaic pyruvic transaminase 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus 
HLA Human leukocyte antigen 
HRP Horse radish peroxidase 
HSC Hepatic stellate cell 
i.p. Intraperitoneal 
i.v. Intravenous 
IFNAR Interferon-α receptor 
ifnb1 Gene that encodes IFN-ȕ 
IFN-α Interferon α 
IFN-ȕ Interferon ȕ 
IgG Immunoglobulin G 
IL Interleukin 
IP-10 Interferon gamma-induced protein 10 (also known as CXCL10) 
IRF IFN regulatory factor 
ISG Interferon stimulated gene 
JNK Jun N-terminal kinase 
KO Knock-out 
LGP2 Laboratory of Genetics and Physiology 2 
LSEC Liver sinusoidal endothelial cell 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MAVS Mitochondrial antiviral-signaling protein 
MDA5 Melanoma differentiation-associated gene 5 
MDSC Myeloid-derived suppressor cell 
MFI Median fluorescence intensity 
MHC Major histocompatibility complex 
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NF-țB Nuclear factor kappa-light-chain-enhancer of activated B-cells 
NK cell Natural killer cell 
Nod Non-obese diabetic 
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NP-40 Nonidet P-40 
NSG mouse Nod-scid mouse 
OH-RNA Unspecific control RNA without 5’ppp-modification 
OS Overall survival 
OV Onkolytic virus 
PAMP Pathogen-associated molecular pattern 
PB Pacific blue 
PBS Phosphate-buffered saline 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed cell death ligand 1 
PE Phycoerythin 
PEI Percutaneous ethanol injection 
PerCP Peridinin chlorophyll 
PFA Paraformaldehyde 
PFA Paraformaldehyde 
PFS Progression free survival 
PFS Progression free survival 
PI Propidium iodide 
pIRF-3 Phosphorylated IRF-3 
ppp-RNA 5´-triphosphate-RNA 
PRR Pattern recognition receptors 
qRT-PCR Quantitative real time PCR 
RAS Rat sarcoma 
RFA Radio frequency ablation 
RIG-I Retinoic acid-inducible gene I 
RIPA Radioimmunoprecipitation assay 
RISC RNA-induced silencing complex 
RLH RIG-I-like helicases 
RNAi RNA interference 
RPMI Roswell Park Memorial Institue 
s.c. Subcutaneous 
Scid Severe combined immunodeficiency 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
siRNA Short interfering RNA 
SMAD Contraction of Sma and Mad 
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STING Stimulator of interferon genes 
TAA Tumor-associated antigens 
TACE Transarterial chemoembolization 
TBS Tris-buffered saline 
TBS-T Tris-buffered saline with Tween 20 
Teff Effector T cells 
TGF-ȕ Transforming growth factor ȕ 
TIL Tumor infiltrating lymphocytes 
TMA Tissue micro array 
Treg Regulatory T cell 
VEGFR Vascular endothelial growth factor receptor 
Wt Wild-type 
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